Amylin analogues

ABSTRACT

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

The present invention relates to amylin analogues that are amylinreceptor agonists, and to their medical use in the treatment and/orprevention of a variety of diseases, conditions or disorders, includingtreatment and/or prevention of excess food intake, obesity and excessbody weight, metabolic diseases, and other conditions and disordersdescribed herein. In particular, the present invention relates to stableamylin analogues that have a long duration of action and are well suitedfor use in the form of a liquid formulation.

BACKGROUND OF THE INVENTION

Amylin is one of a family of peptide hormones that includes amylin,calcitonin, calcitonin gene-related peptide, adrenomedullin andintermedin (intermedin also being known as AFP-6), and has beenimplicated in various metabolic diseases and disorders. Human amylin wasfirst isolated, purified and characterized as the major component ofamyloid deposits in the islets of pancreases from type 2 diabetespatients.

Native human amylin is a 37-amino acid peptide having the formula

(SEQ ID NO: 1) H-KC( )NTATC( )ATQRLANFLVHSSNNFGAILSSINVGSNTY-NH₂wherein H- at the N-terminus designates a hydrogen atom, correspondingto the presence of a free amino group on the N-terminal amino acidresidue [i.e. the lysine (K) residue at sequence position number 1 inthe sequence shown above]; wherein —NH₂ at the C-terminus indicates thatthe C-terminal carboxyl group is in the amide form; and wherein theparentheses ( ) associated with the two cysteine (C, Cys) residues atsequence positions 2 and 7 indicate the presence of an intramoleculardisulfide bridge between the two Cys residues in question.

Amylin may be beneficial in treating metabolic disorders such asdiabetes and/or obesity. Amylin is believed to regulate gastricemptying, and to suppress glucagon secretion and food intake, therebyregulating the rate of glucose release to the circulation. Amylinappears to complement the actions of insulin. Compared to healthyadults, type 1 diabetes patients have no circulating amylin, and type 2diabetes patients exhibit reduced postprandial amylin concentrations. Inhuman trials an amylin analogue known as pramlintide, described in WO93/10146 and having the sequenceLys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr(SEQ ID NO: 2), which also possesses a disulphide bridge between the Cysresidues at positions 2 and 7, has been shown to reduce body weight orreduce weight gain. An alternative amylin analogue incorporatingN-methylated residues and having a reduced tendency to fibrillation,designated IAPP-GI, has been described by Yan et al. (PNAS, 103(7),2046-2051, 2006). IAPP-GI appears to have lower activity than nativeamylin, however. Further analogues of amylin or pramlintide aredescribed in WO2013/156594, WO2012/168430, WO2012/168431 andWO2012/168432, as well as WO2006/042745.

Obesity is believed to be a major causal factor in development of type 2diabetes, which constitutes a growing and worldwide major healthproblem. Diseases or disorders that may develop as a consequence ofuntreated diabetes include cardiovascular and peripheral artery disease,micro- and macrovascular complications, stroke, and certain forms ofcancer, particularly hematopoietic cancers.

There is a need in the art for further amylin analogues. For example,amylin analogues that show a reduced tendency for fibrillation and/orhigh chemical stability at or around pH 7 might allow for a formulationat or near physiological pH. Amylin analogues having high levels ofagonist activity at the amylin receptor and/or appropriately long plasmaelimination half lives, may also enable longer intervals between dosingthan is currently possible (e.g. once weekly, or even less frequently)and hence improve patient compliance.

SUMMARY OF THE INVENTION

The present invention relates to compounds which are analogues of humanamylin.

In a first aspect, the invention provides an amylin analogue which is acompound having the formula:

R¹—Z—R²

whereinR¹ is hydrogen, C₁₋₄ acyl, benzoyl or C₁₋₄ alkyl, or a half-lifeextending moiety M, wherein M is optionally linked to Z via a linkermoiety L;R² is OH or NHR³, wherein R³ is hydrogen or C₁₋₃-alkyl; andZ is an amino acid sequence of formula 1:

(SEQ ID NO: 3) Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-X31-Val-Gly-Ser-X35-Thr- X37 (I);whereinX3 is selected from the group consisting of Asn, Gly, Pro and Gln;X10 is selected from the group consisting of Gln, Asp and Glu;X14 is selected from the group consisting of Asp, His, Asn and Aad;X17 is selected from the group consisting of His, Asn, Gln, Glu, Thr,Val, Lys and Aad;X19-X20 is selected from the group consisting of Ser-Ser, Val-Val,Ser-Val and Val-Ser, or is absent;X31 is selected from the group consisting of Asp, Glu and Asn;X35 is selected from the group consisting of Asp, Glu, Asn, Ser, Phe,Orn, Aad, Gly and Thr; andX37 is selected from the group consisting of Pro, Apr and Hyp;and wherein the compound has at least one residue selected from:

X3 is Gln; X14 is His, Asn or Aad; X17 is Asn, Gln, Glu, Thr or Aad;X19-X20 is Val-Ser or Ser-Val; and X35 is Ser, Phe, Orn, Aad, Gly orThr;

or a pharmaceutically acceptable salt or solvate thereof.

Throughout this specification, amino acid positions of the amylinanalogues are numbered according to the corresponding position in humanamylin having the sequence shown above. The sequence of Formula I (andother formulae herein) contains a two amino acid deletion correspondingto the two residues Asn21 and Asn22 of human amylin. Thus, for ease ofcomparison with the amylin sequence, the Phe residue immediatelyC-terminal (downstream) of position X20 is designated as position 23,since it aligns with Phe23 of human amylin. Thus, the numbering of anygiven residue in Formula I above, and in other formulae elsewhere inthis specification, reflects the corresponding residue in human amylinwhen optimally aligned therewith and does not necessarily reflect itslinear position in the particular sequence.

(It will be apparent that any of the relevant formulae presented in thisspecification could be written to include residues X21-X22 at theappropriate positions, wherein X21 and X22 are absent.)

It has surprisingly been found that simultaneous deletion of theresidues at positions X21 and X22 (and even additionally at positionsX19 and X20) leads to active and stable amylin analogues. Further,without wishing to be bound by any particular theory, it is believedthat the deletion of these residues may enhance the chemical stabilityof the molecules, especially at neutral and/or alkaline pH. Fibrillationand precipitation of the compounds may also be reduced. Thus thecompounds may have superior properties for formulation as compared toexisting amylin analogues.

Furthermore, the compounds described here show similar or even increasedactivity compared to wild type amylin (e.g. agonist activity at thehAMYR3 and/or hAMYR1 and/or hCTR2 receptors), despite being methylatedat the same positions as IAPP-GI (which has lower activity than wildtype amylin).

In some embodiments of formula I it may be desirable that:

X31 is Glu;

X19-X20 is Ser-Ser or is absent; and/or

X37 is Hyp or Pro.

It may be desirable that the amylin analogue contains at least one ofHis14, Asn14, Aad14, Gln17 and Thr17.

If X14 is Asp, then it may be desirable that X17 is Asn, Gln, Glu, Thror Aad. X17 is Gln may be particularly preferred.

In some circumstances, it may be desirable that X35 is not a hydrophobicresidue, e.g. Phe. Such residues may increase tendency towardsfibrillation in some formulations.

Z may be an amino acid sequence of formula II:

(SEQ ID NO: 4) Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35-Thr- X37 (II);whereinX3 is selected from the group consisting of Asn, Gly and Gln;X10 is selected from the group consisting of Gln, Asp and Glu;X14 is selected from the group consisting of Asp, His and Aad;X17 is selected from the group consisting of His, Asn, Gln, Glu, Lys andAad;X19-X20 is Ser-Ser or is absent;X35 is selected from the group consisting of Asp, Glu, Asn, Ser, Orn,Aad, Gly and Thr; andX37 is selected from the group consisting of Pro and Hyp;and wherein the compound has at least one residue selected from:

X3 is Gln; X14 is His or Aad; X17 is Asn, Gln, Glu or Aad; and X35 isSer, Phe, Orn, Aad, Gly or Thr.

In some embodiments of formula II, X17 may be selected from His and Gln.

Z may be an amino acid sequence of formula III:

(SEQ ID NO: 5) Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35-Thr- X37 (III);whereinX3 is selected from the group consisting of Asn, Gly and Gln;X10 is selected from the group consisting of Gln, Asp and Glu;X14 is selected from the group consisting of Asp, His and Aad;X17 is selected from the group consisting of His and Gln;X19-X20 is Ser-Ser or is absent;X35 is selected from the group consisting of Asp, Glu, Asn, Aad and Gly;andX37 is selected from the group consisting of Pro and Hyp;and wherein the compound has at least one residue selected from:

X3 is Gln; X14 is His or Aad; X17 is Gln; and X35 is Aad.

In any of the formulae described above, it may be desirable that:

X10 is selected from Gln and Glu;and/orX35 is selected from Asp, Glu, Asn and Aad, e.g. X35 is selected fromAsp and Asn.

Additionally or alternatively, it may be that X3 is selected from Asnand Gly and/or X17 is Gn. The presence of Gin at position X17 isbelieved to correlate with good levels of chemical and physicalstability.

Additionally or alternatively, X35 is Asn and/or X37 is Hyp.

In some embodiments of the formulae described above:

X3 is Gin;

X10 is selected from Glu and Asp;X14 is selected from His and Aad;X35 is selected from Gly and Asn; andX37 is selected from Pro and Hyp.

In other embodiments of the formulae described above:

X3 is Gly;

X10 is selected from Glu and Asp;X14 is selected from His and Aad;X35 is selected from Gly and Asn; andX37 is selected from Pro and Hyp.

Combinations of specific residues which may be present in any of theamylin analogues described include:

Gly3+Glu10; Asn3+Glu10; Gln3+Glu10; Asn3+Gln10; or Gln3+Asp10.

In some embodiments, X14 is selected from His and Aad, and/or X17 isGln.

For example, the combination of Aad14 and Gln17 appears to provide goodactivity.

Additionally or alternatively, X17 may be Gln, X31 may be Glu and X37may be Hyp, i.e. the analogue may contain the combinationGln17+Glu31+Hyp37.

In some embodiments, X19-X20 is Ser-Ser. In other embodiments X19-X20 isabsent.

Certain residue combinations which may be favourable for chemicalstability include:

X3 is Gly, X10 is Glu and X14 is His;

X3 is selected from Asn and Gln, X10 is Glu and X14 is His;X3 is Gly, X10 is Glu and X14 is selected from Aad and Asp;

X10 is Asp and X14 is Aad;

X14 is selected from Aad and His, X31 is Glu and X37 is selected fromPro and Hyp; and

X14 is Aad, X31 is Glu and X37 is Hyp.

Of these combinations, the following may additionally (or alternatively)have a favourable effect on activity:

X3 is Gly, X10 is Glu and X14 is selected from Aad and Asp;X14 is selected from Aad and His, X31 is Glu and X37 is selected fromPro and Hyp;

X14 is Aad, X31 is Glu and X37 is Hyp.

For example, the compound may comprise the residues:

Gly3+Glu10+His14 Asn3+Glu10+His14; Gln3+Glu10+His14; Gly3+Glu10+Aad14;Gly3+Glu10+Asp14; Asp10+Aad14; His14+Glu31+Pro37 His14+Glu31+Hyp37Aad14+Glu31+Pro37; and Aad14+Glu31+Hyp37.

Yet further combinations of desirable residues include:

Gly3+Glu31; Gly3+Ser19+Ser20+Glu31 Gly3+Glu10+Glu31+Asn35+Hyp37; andGly3+Glu10+Ser19+Ser20+Glu31+Asn35+Hyp37.

Any of the above-described residues and combinations of residues may becombined except where inconsistent with one another.

The invention also provides an amylin analogue which is a compoundhaving the formula:

R¹—Z—R²

whereinR¹ is hydrogen, C₁₋₄ acyl, benzoyl or C₁₋₄ alkyl, or a half-lifeextending moiety M, wherein M is optionally linked to Z via a linkermoiety L;R² is OH or NHR³, wherein R³ is hydrogen or C₁₋₃-alkyl; andZ is an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 99) RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS ETP;(SEQ ID NO: 100) RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVGSNT-Apr; and (SEQ ID NO: 101)RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVG SNT-Apr;or a pharmaceutically acceptable salt or solvate thereof.

Thus, the amylin analogue may have the formula:

R¹—Z—R²

whereinR¹ is hydrogen, C₁₋₄ acyl, benzoyl or C₁₋₄ alkyl, or a half-lifeextending moiety M, wherein M is optionally linked to Z via a linkermoiety L;R² is OH or NHR³, wherein R³ is hydrogen or C₁₋₃-alkyl; andZ is an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 6) RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 7) RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 8) RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 9) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 10) RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 11) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 12) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF T-Hyp(SEQ ID NO: 13) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp (SEQ ID NO: 14)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS- Aad-T-Hyp(SEQ ID NO: 15) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp(SEQ ID NO: 16) RCNTATCATQRLAHFLHRF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP(SEQ ID NO: 17) RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 18) RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 19) RCGTATCATERLANFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 20) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 21) RCGTATCATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 22) RCNTATCATQRLAHFLHRSVF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 23) RCNTATCATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 24) RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 25) RCPTATCATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSD TP(SEQ ID NO: 26) RCNTATCATQRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 27) RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSN TP(SEQ ID NO: 28) RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 29) RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSD TP(SEQ ID NO: 30) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 31) RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 32) RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 33) RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 34) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF T-Hyp(SEQ ID NO: 35) RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF T-Hyp(SEQ ID NO: 36) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 37) RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 38) RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 39) RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 40) RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 41) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF TP(SEQ ID NO: 42) RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF TP(SEQ ID NO: 43) RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 44) RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF T-Hyp(SEQ ID NO: 45) RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp (SEQ ID NO: 46)RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTE VGS-Orn-T-Hyp(SEQ ID NO: 47) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Apr(SEQ ID NO: 48) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 49) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS- Orn-TP(SEQ ID NO: 50) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGST T-Hyp(SEQ ID NO: 51) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 52) RCNTATCATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp (SEQ ID NO: 53)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS- Orn-T-Hyp(SEQ ID NO: 54) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp(SEQ ID NO: 55) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp (SEQ ID NO: 56)RCGTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp (SEQ ID NO: 57)RCGTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE VGSNT-Hyp(SEQ ID NO: 58) RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 59) RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 60) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 61) RCPTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSN T-Hyp(SEQ ID NO: 62) RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSD T-Hyp(SEQ ID NO: 63) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 64) RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 65) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 66) RCPTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 67) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 68) RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 69) RCPTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 70) RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 71) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 72) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp(SEQ ID NO: 73) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp(SEQ ID NO: 74) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp(SEQ ID NO: 75) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGST T-Hyp(SEQ ID NO: 76) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGST T-Hyp(SEQ ID NO: 77) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp (SEQ ID NO: 78)RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS- Aad-T-Hyp(SEQ ID NO: 79) RCGTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT- Hyp(SEQ ID NO: 80) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP(SEQ ID NO: 81) RCNTATCATQRLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT- Hyp(SEQ ID NO: 82) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG TP(SEQ ID NO: 83) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp(SEQ ID NO: 84) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGST TP(SEQ ID NO: 85) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGST T-Hyp(SEQ ID NO: 86) RCNTATCATQRLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 87) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS TP(SEQ ID NO: 88) RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp (SEQ ID NO: 89)RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE VGSST-Hyp(SEQ ID NO: 90) RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp(SEQ ID NO: 91) RCQTATCATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp (SEQ ID NO: 92)RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp (SEQ ID NO: 93)RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp (SEQ ID NO: 94)RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP (SEQ ID NO: 95)RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE VGSNTP (SEQ ID NO: 96)RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE VGSGTP (SEQ ID NO: 97)RCQTATCATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-LSSTEVG SNT-Hyp(SEQ ID NO: 98) RCQTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTPor a pharmaceutically acceptable salt or solvate thereof.

In some embodiments, R¹ is M or M-L-, and/or R² is NH₂.

Specific amylin analogues of the invention include:

(SEQ ID NO: 102)[19CD]-isoGlu-RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 103)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 104)[19CD]-isoGlu-RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 105)[19CD]-isoGlu-RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂(SEQ ID NO: 106)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂(SEQ ID NO: 107)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 108)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 109)[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 110)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 111)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(SEQ ID NO: 112)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(SEQ ID NO: 113)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(SEQ ID NO: 114)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 115)[19CD]-isoGlu-RCNTATCATQRLAHFLHRF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 116)[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 117)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 118)[19CD]-isoGlu-RCGTATCATERLANFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 119)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 120)[19CD]-isoGlu-RCGTATCATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 121)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSVF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 122)[19CD]-isoGlu-RCNTATCATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 123)[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 124)[19CD]-isoGlu-RCPTATCATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂(SEQ ID NO: 125)[19CD]-isoGlu-RCNTATCATQRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 126)[19CD]-isoGlu-RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNTP-NH₂(SEQ ID NO: 127)[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 128)[19CD]-isoGlu-RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂(SEQ ID NO: 129)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 130)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 131)[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 132)[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 133)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(SEQ ID NO: 134)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(SEQ ID NO: 135)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 136)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 137)[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 138)[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 139)[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 140)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂(SEQ ID NO: 141)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂(SEQ ID NO: 142)[19CD]-isoGlu-RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 143)[19CD]-isoGlu-RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(SEQ ID NO: 144)[19CD]-isoGlu-RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 145)[19CD]-isoGlu-RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(SEQ ID NO: 146)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Apr-NH₂(SEQ ID NO: 147)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 148)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-TP-NH₂(SEQ ID NO: 149)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(SEQ ID NO: 150)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 151)[19CD]-isoGlu-RCNTATCATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 152)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(SEQ ID NO: 153)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 154)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(SEQ ID NO: 155)[19CD]-isoGlu-RCGTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 156)[19CD]-isoGlu-RCGTATCATERLA-Aad-FLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 157)[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 158)[19CD]-isoGlu-RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 159)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 160)[19CD]-isoGlu-RCPTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNT-Hyp-NH₂(SEQ ID NO: 161)[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSDT-Hyp-NH₂(SEQ ID NO: 162)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 163)[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 164)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 165)[19CD]-isoGlu-RCPTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 166)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 167)[19CD]-isoGlu-RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 168)[19CD]-isoGlu-RCPTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 169)[19CD]-isoGlu-RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 170)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 171)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 172)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 173)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 174)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(SEQ ID NO: 175)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(SEQ ID NO: 176)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(SEQ ID NO: 177)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(SEQ ID NO: 178)[19CD]-isoGlu-RCGTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 179)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 180)[19CD]-isoGlu-RCNTATCATQRLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 181)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂(SEQ ID NO: 182)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 183)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTTP-NH₂(SEQ ID NO: 184)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(SEQ ID NO: 185)[19CD]-isoGlu-RCNTATCATQRLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 186)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(SEQ ID NO: 187)[19CD]-isoGlu-RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 188)[19CD]-isoGlu-RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(SEQ ID NO: 189)[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 190)[19CD]-isoGlu-RCQTATCATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 191)[19CD]-isoGlu-RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 192)[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(SEQ ID NO: 193)[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 194)[19CD]-isoGlu-RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(SEQ ID NO: 195)[19CD]-isoGlu-RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂(SEQ ID NO: 196)[19CD]-isoGlu-RCQTATCATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(SEQ ID NO: 197)[19CD]-isoGlu-RCQTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂wherein [19CD] represents [19-carboxynonadecanoyl];and pharmaceutically acceptable salts and solvates thereof.

Any of the sequences or compounds described above may possess anintramolecular disulphide bridge formed between the cysteine residuespresent at positions 2 and 7 of the amino acid sequence (numbered fromN- to C-terminus, and corresponding to the cysteine residues present atpositions 2 and 7 of human amylin). In general, it may be desirable thatcompounds possess such a disulphide bridge at the time of administrationto a subject, but it will be understood that the invention extends tocompounds having the specified amino acid sequences before formation ofthe disulphide. The presence of the disulphide may be indicated byparentheses ( ) following each relevant cysteine residue in thesequence. All of the generic and specific formulae provided above shouldbe construed accordingly to include this possibility. Thus, for example,Formulae I, II and III may be shown as follows:

(I) (SEQ ID NO: 3) Arg-Cys( )-X3-Thr-Ala-Thr-Cys( )-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-X31-Val-Gly-Ser-X35- Thr-X37; (II)(SEQ ID NO: 4) Arg-Cys( )-X3-Thr-Ala-Thr-Cys( )-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35- Thr-X37; and (III)(SEQ ID NO: 5) Arg-Cys( )-X3-Thr-Ala-Thr-Cys( )-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35- Thr-X37;while the specific compounds listed above may be designated as follows:

(SEQ ID NO: 102)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 1) (SEQ ID NO: 103)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd.2) (SEQ ID NO: 104)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 3) (SEQ ID NO: 105)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂(Compd. 4) (SEQ ID NO: 106)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂(Compd. 5) (SEQ ID NO: 107)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 6) (SEQ ID NO: 108)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 7) (SEQ ID NO: 109)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 8) (SEQ ID NO: 110)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 9) (SEQ ID NO: 111)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 10) (SEQ ID NO: 112)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-(Compd. 11) (SEQ ID NO: 113)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 12) (SEQ ID NO: 114)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 13) (SEQ ID NO: 115)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 14) (SEQ ID NO: 116)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 15) (SEQ ID NO: 117)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 16). (SEQ ID NO: 118)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLANFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 17) (SEQ ID NO: 119)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 18) (SEQ ID NO: 120)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 19) (SEQ ID NO: 121)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSVF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 20) (SEQ ID NO: 122)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 21) (SEQ ID NO: 123)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 22) (SEQ ID NO: 124)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂(Compd. 23) (SEQ ID NO: 125)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 24) (SEQ ID NO: 126)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNTP-NH₂(Compd. 25) (SEQ ID NO: 127)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 26) (SEQ ID NO: 128)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂(Compd. 27) (SEQ ID NO: 129)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 28) (SEQ ID NO: 130)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 29) (SEQ ID NO: 131)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 30) (SEQ ID NO: 132)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 31) (SEQ ID NO: 133)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 32) (SEQ ID NO: 134)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 33) (SEQ ID NO: 135)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 34) (SEQ ID NO: 136)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 35) (SEQ ID NO: 137)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 36) (SEQ ID NO: 138)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 37) (SEQ ID NO: 139)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 38) (SEQ ID NO: 140)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂(Compd. 39) (SEQ ID NO: 141)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂(Compd. 40) (SEQ ID NO: 142)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 41) (SEQ ID NO: 143)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 42) (SEQ ID NO: 144)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST- Hyp-NH₂(Compd. 43) (SEQ ID NO: 145)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(Compd. 44) (SEQ ID NO: 146)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Apr-NH₂(Compd. 45) (SEQ ID NO: 147)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 46) (SEQ ID NO: 148)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-TP-NH₂(Compd. 47) (SEQ ID NO: 149)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 48) (SEQ ID NO: 150)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 49) (SEQ ID NO: 151)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 50) (SEQ ID NO: 152)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(Compd. 51) (SEQ ID NO: 153)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 52) (SEQ ID NO: 154)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 53) (SEQ ID NO: 155)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 54) (SEQ ID NO: 156)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 55) (SEQ ID NO: 157)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 56) (SEQ ID NO: 158)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 57) (SEQ ID NO: 159)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 58) (SEQ ID NO: 160)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNT-Hyp-NH₂(Compd. 59) (SEQ ID NO: 161)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSDT-Hyp-NH₂(Compd. 60) (SEQ ID NO: 162)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 61) (SEQ ID NO: 163)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 62) (SEQ ID NO: 164)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 63) (SEQ ID NO: 165)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 64) (SEQ ID NO: 166)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 65) (SEQ ID NO: 167)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 66) (SEQ ID NO: 168)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 67) (SEQ ID NO: 169)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 68) (SEQ ID NO: 170)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 69) (SEQ ID NO: 171)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 70) (SEQ ID NO: 172)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 71) (SEQ ID NO: 173)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 72) (SEQ ID NO: 174)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 73) (SEQ ID NO: 175)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 74) (SEQ ID NO: 176)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 75) (SEQ ID NO: 177)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 76) (SEQ ID NO: 178)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 77) (SEQ ID NO: 179)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 78) (SEQ ID NO: 180)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 79) (SEQ ID NO: 181)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂(Compd. 80) (SEQ ID NO: 182)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 81) (SEQ ID NO: 183)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTTP-NH₂(Compd. 82) (SEQ ID NO: 184)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 83) (SEQ ID NO: 185)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 84) (SEQ ID NO: 186)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 85) (SEQ ID NO: 187)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 86) (SEQ ID NO: 188)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 87) (SEQ ID NO: 189)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 88) (SEQ ID NO: 190)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 89) (SEQ ID NO: 191)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 90) (SEQ ID NO: 192)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 91) (SEQ ID NO: 193)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 92) (SEQ ID NO: 194)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 93) (SEQ ID NO: 195)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂(Compd. 94) (SEQ ID NO: 196)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 95) (SEQ ID NO: 197)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 96)wherein [19CD] represents [19-carboxynonadecanoyl];and pharmaceutically acceptable salts and solvates thereof.

In certain embodiments, the amylin analogue of the invention is not acompound having the formula:

R¹—Z—R²

whereinR¹ is hydrogen, C₁₋₄ acyl, benzoyl or C₁₋₄ alkyl, or a half-lifeextending moiety M, wherein M is optionally linked to Z via a linkermoiety L;R² is OH or NHR³, wherein R³ is hydrogen or C₁₋₃-alkyl; andZ is an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 99) RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 6) RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 7) RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSE TP(SEQ ID NO: 100) RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVGSNT-Apr (SEQ ID NO: 101)RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVG SNT-Apr (SEQ ID NO: 8)RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp (SEQ ID NO: 9)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp (SEQ ID NO: 10)RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN T-Hyp (SEQ ID NO: 11)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSS T-Hyp (SEQ ID NO: 12)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSF T-Hyp (SEQ ID NO: 13)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS- Orn-T-Hyp(SEQ ID NO: 14) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp (SEQ ID NO: 15)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSG T-Hyp (SEQ ID NO: 16)RCNTATCATQRLAHFLHRF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP (SEQ ID NO: 17)RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TP and (SEQ ID NO: 18)RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSN TPor a pharmaceutically acceptable salt or solvate thereof.

For example, in such embodiments, the compound is not:

(SEQ ID NO: 102) [19CD]-isoGlu-RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂ (SEQ ID NO: 103)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 104) [19CD]-isoGlu-RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂ (SEQ ID NO: 105)[19CD]-isoGlu-RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂ (SEQ ID NO: 106)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂ (SEQ ID NO: 107)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂ (SEQ ID NO: 108)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂ (SEQ ID NO: 109)[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂ (SEQ ID NO: 110)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂ (SEQ ID NO: 111)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂ (SEQ ID NO: 112)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂ (SEQ ID NO: 113)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂ (SEQ ID NO: 114)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂ (SEQ ID NO: 115)[19CD]-isoGlu-RCNTATCATQRLAHFLHRF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂(SEQ ID NO: 116) [19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂ or (SEQ ID NO: 117)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂;(wherein [19CD] represents [19-carboxynonadecanoyl])and pharmaceutically acceptable salts and solvates thereof;or any such compounds comprising an intramolecular disulphide bridgeformed between the cysteine residues present at positions 2 and 7 of theamino acid sequence.

The invention further provides a composition comprising an amylinanalogue as described above. The composition may be a pharmaceuticalcomposition, and may comprise a pharmaceutically acceptable carrier,excipient or vehicle.

The invention further provides a method for the synthesis of an amylinanalogue as described above. The method may comprise the steps ofsynthesising the peptide by solid-phase or liquid-phase methodology, andoptionally isolating and/or purifying the final product. The method mayfurther comprise the step of forming a disulphide bond between the thiolgroups of the cysteine side chains at positions 2 and 7.

The present invention further provides an amylin analogue of theinvention for use in a method of medical treatment.

The amylin analogues are useful, inter alia, in the reduction of foodintake, promotion of weight loss, and inhibition or reduction of weightgain. As a result, they may be used for treatment of a variety ofconditions, diseases, or disorders in a subject, including, but notlimited to, obesity and various obesity-related conditions, diseases, ordisorders, such as diabetes (e.g. type 2 diabetes), hypertension,dyslipidemia, sleep apnea and cardiovascular disease. The subject may beaffected by obesity accompanied by at least one weight-related co-morbidcondition, such as diabetes (e.g. type 2 diabetes), hypertension,dyslipidemia, sleep apnea and cardiovascular disease. It will beunderstood that the amylin analogues may thus be administered tosubjects affected by conditions characterised by inadequate control ofappetite or otherwise over-feeding, such as binge-eating disorder andPrader-Willi syndrome. It will be clear that the analogues can be usedfor treatment of combinations of the conditions described.

Thus, the invention provides an amylin analogue of the invention for usein a method of treating, inhibiting or reducing weight gain, promotingweight loss and/or reducing excess body weight. Treatment may beachieved, for example, by control of appetite, feeding, food intake,calorie intake and/or energy expenditure.

The invention also provides an amylin analogue of the invention for usein a method of treating obesity as well as associated diseases,disorders and health conditions, including, but not limited to, morbidobesity, obesity prior to surgery, obesity-linked inflammation,obesity-linked gallbladder disease and obesity-induced sleep apnea andrespiratory problems, degeneration of cartilage, osteoarthritis, andreproductive health complications of obesity or overweight such asinfertility. The subject may be affected by obesity accompanied by atleast one weight-related co-morbid condition, such as diabetes (e.g.type 2 diabetes), hypertension, dyslipidemia, sleep apnea andcardiovascular disease.

The invention also provides an amylin analogue of the invention for usein a method of prevention or treatment of Alzheimer's disease, diabetes,type 1 diabetes, type 2 diabetes, pre-diabetes, insulin resistancesyndrome, impaired glucose tolerance (IGT), disease states associatedwith elevated blood glucose levels, metabolic disease includingmetabolic syndrome, hyperglycemia, hypertension, atherogenicdyslipidemia, hepatic steatosis (“fatty liver”; including non-alcoholicfatty liver disease (NAFLD), which itself includes non-alcoholicsteatohepatitis (NASH)), kidney failure, arteriosclerosis (e.g.atherosclerosis), macrovascular disease, microvascular disease, diabeticheart (including diabetic cardiomyopathy and heart failure as a diabeticcomplication) coronary heart disease, peripheral artery disease orstroke, and combinations thereof.

The invention also provides an amylin analogue of the invention for usein a method of lowering circulating LDL levels and/or increasing HDL/LDLratio.

Effects of amylin analogues on these conditions may be mediated in wholeor in part via an effect on body weight, or may be independent thereof.

The invention further provides use of an amylin analogue of theinvention in the manufacture of a medicament for treating, inhibiting orreducing weight gain, promoting weight loss and/or reducing excess bodyweight.

The invention also provides use of an amylin analogue of the inventionin the manufacture of a medicament for treating obesity as well asassociated diseases, disorders and health conditions, including, but notlimited to, morbid obesity, obesity prior to surgery, obesity-linkedinflammation, obesity-linked gallbladder disease and obesity-inducedsleep apnea and respiratory problems, degeneration of cartilage,osteoarthritis, and reproductive health complications of obesity oroverweight such as infertility. The subject may be affected by obesityaccompanied by at least one weight-related co-morbid condition, such asdiabetes (e.g. type 2 diabetes), hypertension, dyslipidemia, sleep apneaand cardiovascular disease.

The invention also provides use of an amylin analogue of the inventionin the manufacture of a medicament for the prevention or treatment ofAlzheimer's disease, diabetes, type 1 diabetes, type 2 diabetes,pre-diabetes, insulin resistance syndrome, impaired glucose tolerance(IGT), disease states associated with elevated blood glucose levels,metabolic disease including metabolic syndrome, hyperglycemia,hypertension, atherogenic dyslipidemia, hepatic steatosis (“fattyliver”; including non-alcoholic fatty liver disease (NAFLD), whichitself includes non-alcoholic steatohepatitis (NASH)), kidney failure,arteriosclerosis (e.g. atherosclerosis), macrovascular disease,microvascular disease, diabetic heart (including diabetic cardiomyopathyand heart failure as a diabetic complication) coronary heart disease,peripheral artery disease or stroke, and combinations thereof.

The invention also provides use of an amylin analogue of the inventionin the manufacture of a medicament for lowering circulating LDL levelsand/or increasing HDL/LDL ratio.

The invention further provides a method of treating, inhibiting orreducing weight gain, promoting weight loss and/or reducing excess bodyweight in a subject, comprising administering a therapeuticallyeffective amount of an amylin analogue of the invention to the subject.

The invention also provides a method of treating obesity as well asassociated diseases, disorders and health conditions, including, but notlimited to, morbid obesity, obesity prior to surgery, obesity-linkedinflammation, obesity-linked gallbladder disease and obesity-inducedsleep apnea and respiratory problems, degeneration of cartilage,osteoarthritis, and reproductive health complications of obesity oroverweight such as infertility in a subject, comprising administering atherapeutically effective amount of an amylin analogue of the inventionto the subject. The subject may be affected by obesity accompanied by atleast one weight-related co-morbid condition, such as diabetes (e.g.type 2 diabetes), hypertension, dyslipidemia, sleep apnea andcardiovascular disease.

The invention also provides a method of prevention or treatment ofAlzheimer's disease, diabetes, type 1 diabetes, type 2 diabetes,pre-diabetes, insulin resistance syndrome, impaired glucose tolerance(IGT), disease states associated with elevated blood glucose levels,metabolic disease including metabolic syndrome, hyperglycemia,hypertension, atherogenic dyslipidemia, hepatic steatosis (“fattyliver”; including non-alcoholic fatty liver disease (NAFLD), whichitself includes non-alcoholic steatohepatitis (NASH)), kidney failure,arteriosclerosis (e.g. atherosclerosis), macrovascular disease,microvascular disease, diabetic heart (including diabetic cardiomyopathyand heart failure as a diabetic complication) coronary heart disease,peripheral artery disease or stroke, and combinations thereof, in asubject, comprising administering a therapeutically effective amount ofan amylin analogue of the invention to the subject.

The invention further provides a method of lowering circulating LDLlevels and/or increasing HDL/LDL ratio in a subject, comprisingadministering a therapeutically effective amount of an amylin analogueof the invention to the subject.

The invention further provides the use of an amylin analogue asdescribed above in a method of cosmetic (i.e. non-therapeutic) weightloss. It will be understood that references to therapeutic uses ofamylin analogues and methods comprising administration of amylinanalogues may equally be taken to encompass uses and administration ofsuch compositions.

Further aspects and embodiments of the present invention will becomeapparent from the disclosure below.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise defined herein, scientific and technical terms usedherein shall have the meanings that are commonly understood by those ofordinary skill in the art. Generally, nomenclature employed herein inconnection with techniques of chemistry, molecular biology, cell andcancer biology, immunology, microbiology, pharmacology, and protein andnucleic acid chemistry, described herein, is that well known andcommonly used in the art.

All publications, patents and published patent applications referred toin this application are specifically incorporated by reference herein.In case of conflict, the present specification, including its specificdefinitions, will control.

Throughout this specification, the word “comprise” or variations such as“comprises” or “comprising” will be understood to imply the inclusion ofa stated integer or component, or of a stated group of integers orcomponents, but not the exclusion of any other integer or component orgroup of integers or components.

The singular forms “a,” “an,” and “the” include the plurals unless thecontext clearly dictates otherwise.

The term “including” is used to mean “including but not limited to.”“Including” and “including but not limited to” are used interchangeably.

The terms “patient”, “subject,” and “individual” may be usedinterchangeably and may refer to either a human or a non-human animal.Subjects are typically mammals, including humans, non-human primates(including great apes, Old World monkeys and New World monkeys),livestock animals (e.g., bovines, porcines), companion animals (e.g.,canines, felines) and rodents (e.g., mice and rats).

As used herein, the term “pharmaceutically acceptable salt” is intendedto indicate a salt which is not harmful to a patient or subject to whichthe salt in question is administered. It may suitably be a salt chosen,e.g., among acid addition salts and basic salts. Examples of acidaddition salts include chloride salts, citrate salts and acetate salts.Examples of basic salts include salts where the cation is selected amongalkali metal cations, such as sodium or potassium ions, alkaline earthmetal cations, such as calcium or magnesium ions, as well as substitutedammonium ions, such as ions of the type N(R₁)(R²)(R³)(R⁴)⁺, where R¹,R², R³ and R⁴ independently will typically designate hydrogen,optionally substituted C₁₋₆-alkyl or optionally substitutedC₂₋₆-alkenyl. Examples of relevant C₁₋₆-alkyl groups include methyl,ethyl, 1-propyl and 2-propyl groups. Examples of C₂₋₆-alkenyl groups ofpossible relevance include ethenyl, 1-propenyl and 2-propenyl. Otherexamples of pharmaceutically acceptable salts are described in“Remington's Pharmaceutical Sciences”, 17th edition, Alfonso R. Gennaro(Ed.), Mark Publishing Company, Easton, Pa., USA, 1985 (and more recenteditions thereof), in the “Encyclopaedia of Pharmaceutical Technology”,3^(rd) edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.),NY, USA, 2007, and in J. Pharm. Sci. 66: 2 (1977).

The term “solvate” in the context of the present invention refers to acomplex of defined stoichiometry formed between a solute (in casu, apeptide or pharmaceutically acceptable salt thereof according to theinvention) and a solvent. The solvent in this connection may, forexample, be water, ethanol or another pharmaceuticallyacceptable—typically small-molecular-organic species, such as, but notlimited to, acetic acid or lactic acid. When the solvent in question iswater, such a solvate is normally referred to as a hydrate.

The term “agonist” as employed in the context of the invention refers toa substance that activates the receptor type in question, typically bybinding to it (i.e. as a ligand).

Each embodiment of the invention described herein may be taken alone orin combination with one or more other embodiments of the invention.

Throughout the present specification, unless naturally occurring aminoacids are referred to by their full name (e.g. alanine, arginine, etc.),they are designated by their conventional three-letter or single-letterabbreviations (e.g. Ala or A for alanine, Arg or R for arginine, etc.).In the case of certain less common or non-naturally occurring aminoacids (i.e. amino acids other than the 20 encoded by the standardmammalian genetic code), unless they are referred to by their full name(e.g. sarcosine, ornithine, etc.), frequently employed three- orfour-character codes are employed for residues thereof, including Orn(ornithine, i.e. 2,5-diaminopentanoic acid), Aib (α-aminoisobutyricacid), Dab (2,4-diaminobutanoic acid), Dap (2,3-diaminopropanoic acid),Har (homoarginine), γ-Glu (γ-glutamic acid), Gaba (γ-aminobutanoicacid), β-Ala (i.e. 3-aminopropanoic acid), 8Ado(8-amino-3,6-dioxaoctanoic acid).

Unless otherwise indicated, reference is made to the L-isomeric forms ofthe amino acids in question.

Additional abbreviations include the following:

-   Gly(Me): N-methylglycine [also known as sarcosine (Sar)]-   Ile(Me): N-methylisoleucine-   Aad: 2-aminoadipic acid, e.g. (2S)-2-aminoadipic acid [also    (2S)-2-aminohexanedioic acid], also known as homo-glutamic acid-   Apr: 4-aminoproline, e.g. (2S,4R)-4-aminoproline    -   [also denoted (4R)-4-amino-L-proline]-   Hyp: 4-hydroxyproline, e.g. (2S,4R)-4-hydroxyproline    -   [also denoted (4R)-4-hydroxy-L-proline]

The term “therapeutically effective amount” as used herein in thecontext of the above-described methods of treatment or other therapeuticinterventions according to the invention refers to an amount that issufficient to cure, ameliorate, alleviate or partially arrest theclinical manifestations of the particular disease, disorder or conditionthat is the object of the treatment or other therapeutic intervention inquestion e.g. as measured by established clinical endpoints or otherbiomarkers (established or experimental). A therapeutically relevantamount may be determined empirically by one skilled in the art based onthe indication being treated or prevented and the subject to whom thetherapeutically relevant amount is being administered. For example, theskilled worker may measure one or more of the clinically relevantindicators of bioactivity described herein, e.g. plasma lipid levels,blood glucose levels or insulin release. The skilled worker maydetermine a clinically relevant amount through in vitro or in vivomeasurements. Other exemplary measures include weight gain, weight loss,and change in blood pressure.

An amount adequate to accomplish any or all of these effects is definedas a therapeutically effective amount. The administered amount and themethod of administration can be tailored to achieve optimal efficacy. Anamount effective for a given purpose will depend, inter alia, on theseverity of the disease, disorder or condition that is the object of theparticular treatment or other therapeutic intervention, on the bodyweight and general condition of the subject in question, on diet, onpossible concurrent medication, and on other factors well known to thoseskilled in the medical arts. Determination of an appropriate dosage sizeand dosing regimen most appropriate for administration of a peptide orpharmaceutically acceptable salt or solvate thereof according to theinvention to a human may be guided by the results obtained by thepresent invention, and may be confirmed in properly designed clinicaltrials. An effective dosage and treatment protocol may be determined byconventional means, starting with a low dose in laboratory animals andthen increasing the dosage while monitoring the effects, andsystematically varying the dosage regimen as well. Numerous factors maybe taken into consideration by a clinician when determining an optimaldosage for a given subject. Such considerations are well known to theskilled person.

The terms “treatment” and grammatical variants thereof (e.g. “treated”,“treating”, “treat”) as employed in the present context refer to anapproach for obtaining beneficial or desired clinical results. For thepurposes of this invention, beneficial or desired clinical resultsinclude, but are not limited to, alleviation of symptoms, diminishmentof extent of disease, stabilization (i.e. not worsening) of state ofdisease, delay or slowing of disease progression, amelioration orpalliation of the disease state, and remission (whether partial ortotal), whether detectable or undetectable. “Treatment” can also meanprolonging survival relative to expected survival time if not receivingtreatment. A subject (e.g. a human) in need of treatment may thus be asubject already afflicted with the disease or disorder in question. Theterm “treatment” includes inhibition or reduction of an increase inseverity of a pathological state or symptoms (e.g. weight gain orhyperglycemia) relative to the absence of treatment, and is notnecessarily meant to imply complete cessation of the relevant disease,disorder or condition.

The terms “prevention” and grammatical variants thereof (e.g.,“prevented”, “preventing”, “prevent”) as employed in the present contextrefer to an approach for hindering or preventing the development of, oraltering the pathology of, a condition, disease or disorder.Accordingly, “prevention” may refer to prophylactic or preventivemeasures. For the purposes of this invention, beneficial or desiredclinical results include, but are not limited to, prevention or slowingof symptoms, progression or development of a disease, whether detectableor undetectable. A subject (e.g. a human) in need of “prevention” maythus be a subject not yet afflicted with the disease or disorder inquestion. The term “prevention” thus includes inhibiting or slowing theonset of disease relative to the absence of treatment, and is notnecessarily meant to imply permanent prevention of the relevant disease,disorder or condition.

Synthesis of Amylin Analogues

The invention further provides a method of synthesis of an amylinanalogue of the invention. The amylin analogues (which may also bereferred to as compounds or peptides) may suitably be manufactured bystandard synthetic methods. Thus, the peptides may be synthesized by,e.g., methods comprising synthesizing the peptide by standardsolid-phase or liquid-phase methodology, either stepwise or by fragmentassembly, and optionally isolating and purifying the final peptideproduct. In this context, reference may be made to WO 98/11125 or, interalia, Fields, G. B. et al., “Principles and Practice of Solid-PhasePeptide Synthesis”; in: Synthetic Peptides, Gregory A. Grant (ed.),Oxford University Press (2^(nd) edition, 2002) and the synthesisexamples herein. The method may further comprise the step of forming adisulfide bond between the thiol groups of the cysteine side chains atpositions 2 and 7, e.g. by oxidative cyclisation. In the case of solidphase synthesis, cyclisation may be performed in situ on the solid phase(e.g. resin), i.e. before removal of the peptide from the solid phase.

C₁₋₄ Acyl Groups

C₁₋₄ acyl groups that may be present as a group R¹ in the context ofcompounds of the present invention include formyl (i.e. methanoyl),acetyl (i.e. ethanoyl), propanoyl, 1-butanoyl and 2-methylpropanoylgroups.

C₁₋₄ Alkyl Groups

C₁₋₄ alkyl groups that may be present as a group R¹ in the context ofcompounds of the present invention include, but are not limited to, C₁₋₃alkyl groups, such as methyl, ethyl, 1-propyl or 2-propyl.

C₁₋₃ Alkyl Groups

C₁₋₃ alkyl groups that may be present as a group R³ in the context ofcompounds of the present invention include methyl, ethyl, 1-propyl and2-propyl.

Half-Life Extending Moieties M

As described herein, the N-terminal moiety R¹ in a compound of theinvention may be a half-life extending moiety (sometimes referred to inthe literature as, inter alia, a duration enhancing moiety or albuminbinding moiety), optionally linked (covalently attached) to the peptidemoiety Z via a linker moiety L. Among suitable half-life extendingmoieties are certain types of lipophilic substituents. Without wishingto be bound by any particular theory, it is thought that such lipophilicsubstituents (and other classes of half-life extending moieties) bindalbumin in the blood stream, thereby shielding the compound of theinvention from renal filtration as well as enzymatic degradation andthus possibly enhancing the half-life of the compound in vivo. Thelipophilic substituent may also modulate the potency of the compound asan agonist to the amylin (calcitonin) receptor.

The lipophilic substituent may be attached to the N-terminal amino acidresidue or to the linker L via an ester, a sulfonyl ester, a thioester,an amide, an amine or a sulfonamide. Accordingly it will be understoodthat preferably the lipophilic substituent includes an acyl group, asulfonyl group, an N atom, an O atom or an S atom which forms part ofthe ester, sulfonyl ester, thioester, amide, amine or sulfonamide.Preferably, an acyl group in the lipophilic substituent forms part of anamide or ester with the amino acid residue or the linker.

The lipophilic substituent may comprise a hydrocarbon chain having from10 to 24 C atoms, e.g. from 14 to 22 C atoms, e.g. from 16 to 20 Catoms. Preferably it has at least 14 C atoms, and preferably has 20 Catoms or fewer. For example, the hydrocarbon chain may contain 14, 15,16, 17, 18, 19 or 20 carbon atoms. The hydrocarbon chain may be linearor branched, and may be saturated or unsaturated. Furthermore, it caninclude a functional group at the end of the lipophilic chain, e.g. acarboxylic acid group which may or may not be protected duringsynthesis. From the discussion above it will be understood that thehydrocarbon chain is preferably substituted with a moiety which formspart of the attachment to the N-terminal amino acid residue of thepeptide moiety Z or to the linker L, for example an acyl group, asulfonyl group, an N atom, an O atom or an S atom.

Most preferably, the hydrocarbon chain is substituted with an acylgroup, and accordingly the hydrocarbon chain may be part of an alkanoylgroup, for example a dodecanoyl, 2-butyloctanoyl, tetradecanoyl,hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl or eicosanoylgroup. Examples of functionalized hydrocarbon chains are15-carboxy-pentadecanoyl, 17-carboxy-heptadecanoyl and19-carboxy-nonadecanoyl.

As mentioned above, a lipophilic substituent M may be linked to theN-terminal amino acid residue of Z via a linker L. In embodiments, thelinker moiety L may itself comprise one, two, three or more linkedsub-moieties L¹, L², L³, . . . etc. When the linker L comprises only onesuch moiety, it is attached to the lipophilic substituent and to theN-terminal amino acid residue of Z. The linker may then be attached tothe lipophilic substituent and to the N-terminal amino acid residue of Zindependently by means of an ester, a sulfonyl ester, a thioester, anamide, an amine or a sulfonamide bond. Accordingly, it may include twomoieties independently selected from acyl, sulfonyl, an N atom, an Oatom and an S atom. The linker may consist of a linear or branched C₁₋₁₀hydrocarbon chain or more preferably a linear C₁₋₅ hydrocarbon chain.Furthermore the linker can be substituted with one or more substituentsselected from C₁₋₆ alkyl, amino C₁₋₆ alkyl, hydroxy C₁₋₆ alkyl andcarboxy C₁₋₆ alkyl.

In some embodiments the linker may be, for example, a residue of anynaturally occurring or non-naturally occurring amino acid. For example,the linker may be a residue of Gly, Pro, Ala, Val, Leu, lie, Met, Cys,Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, α-Glu, γ-Glu, ε-Lys, Asp, β-Asp,Ser, Thr, Gaba, Aib, β-Ala (i.e. 3-aminopropanoyl), 4-aminobutanoyl,5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl,9-aminononanoyl, 10-aminodecanoyl or 8Ado (i.e.8-amino-3,6-dioxaoctanoyl).

References to γ-Glu, ε-Lys, and β-Asp indicate residues of amino acidswhich participate in bonds via their side chain carboxyl or aminefunctional groups. Thus γ-Glu, and β-Asp participate in bonds via theiramino and side chain carboxyl groups, while ε-Lys participates via itscarboxyl and side chain amino groups.

In certain embodiments, the linker is a residue of Glu, γ-Glu, E-Lys,β-Ala, 4-aminobutanoyl, 8-aminooctanoyl or 8Ado. In the context of thepresent invention, γ-Glu and isoGlu are used interchangeably.

An example of a lipophilic substituent comprising a lipophilic moiety Mand linker L is shown in the formula below:

Here, the backbone nitrogen of an Arg residue is covalently attached toa γ-Glu linker (L) via an amide linkage. A 19-carboxy-nonadecanoyl groupis covalently attached to the γ-Glu linker via an amide linkage. Thiscombination of lipophilic moiety and linker, attached to an Arg residue,may be referred to by the shorthand notation [19CD]-isoGlu-R, e.g. whenshown in formulae of specific compounds.

The skilled person will be well aware of suitable techniques forpreparing the compounds employed in the context of the invention. Forexamples of suitable chemistry, see, e.g., WO98/08871, WO00/55184,WO00/55119, Madsen et al (J. Med. Chem. 2007, 50, 6126-32), and Knudsenet al. 2000 (J. Med Chem. 43, 1664-1669).

The hydrocarbon chain in a lipophilic substituent may be furthersubstituted. For example, it may be further substituted with up to threesubstituents selected from NH₂, OH and COOH. If the hydrocarbon chain isfurther substituted, it is preferably further substituted with only onesubstituent. Alternatively or additionally, the hydrocarbon chain mayinclude a cycloalkane or heterocycloalkane moiety, for example as shownbelow:

In some embodiments, the cycloalkane or heterocycloalkane moiety is asix-membered ring, e.g. a piperidine ring.

In alternative embodiments of the present invention, the N-terminalamino acid of Z in a compound of the invention may be linked (covalentlyattached) to a biotinylic substituent, optionally via a linker moiety L.Without wishing to be bound by any particular theory, it is likewisebelieved that such biotinylic substituents bind to albumin in the bloodstream, thereby shielding the compound of the invention from enzymaticdegradation and thus possibly enhancing the half-life of the compound invivo. A linker, when present, may provide spacing between the peptidemoiety Z and the biotinylic substituent.

The biotinylic substituent may be attached to the N-terminal amino acidresidue or to the linker via an maleimide ester bond, a sulfonyl esterbond, a thioester bond, an amide bond, an amine bond or a sulfonamidebond. Accordingly it will be understood that the biotinylic substituentpreferably comprises an maleimido group, an acyl group, a sulfonylgroup, an N atom, an O atom or an S atom which forms part of the ester,sulfonyl ester, thioester, amide, amine or sulfonamide bond in question.

Examples of biotinylic substituents may include

Biotin is known as Vitamin H or Coenzyme R, and is a water-solubleB-complex vitamin (vitamin B7). It has been shown to increase oraluptake of certain drugs.

Efficacy of Compounds

The compounds of the invention are amylin receptor agonists, i.e. theyare capable of binding to, and inducing signalling by, one or morereceptors or receptor complexes regarded as physiological receptors forhuman amylin. These include the human calcitonin receptor hCTR2, as wellas complexes comprising the human calcitonin receptor hCTR2 and at leastone of the human receptor activity modifying proteins designated hRAMP1,hRAMP2 and hRAMP3. Complexes between hCTR2 and hRAMP1, hRAMP2 and hRAMP3are designated hAMYR1, hAMYR2 and hAMYR3 (i.e. human amylin receptors 1,2 and 3) respectively.

Without wishing to be bound by theory, a compound may be considered anamylin receptor agonist if it has agonist activity at one or more ofhAMYR1, hAMYR2 and hAMYR3, e.g. against hAMYR1 and/or hAMYR3, e.g. athAMYR3.

Typically an amylin receptor agonist will also have agonist activity athCTR2 when expressed in the absence of hRAMP1, hRAMP2 and hRAMP3.Typically, the agonist will have activity at hCTR2 (when expressed inthe absence of hRAMP1, hRAMP2 and hRAMP3) which is less than 10-foldhigher than its activity at any one of hAMYR1, hAMYR2 and hAMYR3 (i.e.its activity at all of these receptors) in a comparable assay. Agonistactivity at hCTR2 may be less than 5-fold higher than agonist activityat hAMYR1, hAMYR2 and hAMYR3, substantially equal to (e.g. +/−10%)agonist activity at hAMYR1, hAMYR2 and hAMYR3, or less than agonistactivity at hAMYR1, hAMYR2 and hAMYR3. In this regard, it may besufficient just to compare activity between hCTR2 and hAMYR3.

The ability to induce cAMP formation (i.e. to induce adenylate cyclaseactivity) as a result of binding to the relevant receptor or receptorcomplex is typically regarded as indicative of agonist activity. Otherintracellular signaling pathways or events may also be used as read-outsfor amylin receptor agonist activity. These may include calcium release,β-arrestin recruitment, receptor internalization, kinase activation orinactivation, lipase activation, inositol phosphate release,diacylglycerol release or nuclear transcription factor translocation.

A suitable comparable assay format would utilize cells which expresshCTR2 and which differ only in their expression of hRAMP1, 2 and 3. Forexample, a “base” cell line which does not express any of hCTR2, hRAMP1,hRAMP2 and hRAMP3 may be engineered to generate cells which express (i)hCTR2, and (ii) one of hAMYR1, hAMYR2 and hAMYR3 (i.e. hCTR2 plus one ofhRAMP1, hRAMP2 and hRAMP3), e.g. hAMYR3. The base cells will typicallybe mammalian cells and may be primate cells. They may be non-humanprimate cells. Preferably the base cell does not express any of CTR2,RAMP1, RAMP2 or RAMP3 (whether human, or native to the base cell if thebase cell is non-human). The base cells may be fibroblast cells.Suitable non-human fibroblast base cells include COS7 cells, fromAfrican green monkey, which do not express native CTR2 or RAMPs.

Comparative activity may be measured by any suitable means, such as viadetermination of EC₅₀ values as described below. It will be apparentthat the same biological read-out must be for both receptor types.

Compounds of the present invention may exhibit a number of advantageousproperties in relation to human amylin and existing analogues thereof,such as pramlinitide, IAPP-GI, and analogues described in WO2012/168430,WO2012/168431 and WO2012/168432. As compared to human amylin or any ofthose analogues, compounds of the invention may, for example, exhibitimproved efficacy (e.g., in the form of improved in vitro activity orpotency at one or more of the receptors hCTR2, hAMRY1, hAMRy2 or hAMYR3.Additionally or alternatively, compounds of the invention may exhibitimproved solubility in aqueous media, especially at pH values in therange from 4 to 7.5, or at a range of pH values across that range.Moreover, compounds of the present invention may additionally oralternatively exhibit reduced tendency to undergo fibrillation inpharmaceutically relevant aqueous media, especially at pH values in therange from 4 to 7, or at a range of pH values across that range.Furthermore, compounds of the present invention may additionally oralternatively exhibit improved chemical stability (i.e. reduced tendencyto undergo chemical degradation) in aqueous media, especially at pHvalues in the range from 4 to 9, or at a range of pH values across thatrange.

Compounds of the invention may thus be well suited for formulation inacidic media (e.g. pH 4) and in neutral or near-neutral media (e.g. pH 7or 7.4). In contrast to pramlintide, for example, which generallyexhibits poor chemical stability and rapid fibrillation inpharmaceutically relevant aqueous media at neutral pH, compounds of theinvention may be thus well suited for co-formulation with, for example,insulin, various insulin analogues and/or other therapeutic (e.g.anti-diabetic or anti-obesity) agents that require a neutral ornear-neutral formulation pH.

In general it is preferred to use a biological assay which measuresintracellular signalling caused by binding of the compound to therelevant receptor, as discussed above. Activation of thecalcitonin/amylin receptor by compounds of the invention (which behaveas agonists of the receptor) induces cAMP formation and activation ofother intracellular signaling pathways and events. Thus, production ofcAMP or any other suitable parameter in suitable cells expressing thereceptor can be used to monitor agonist activity towards the receptor.

The skilled person will be aware of suitable assay formats, and examplesare provided below. For example, the assays may make use of the humancalcitonin receptor (hCTR2) having primary accession number GI: 4502547(NP_001733.1) or the hAMYR3 receptor (see Example 2, below). Wheresequences of precursor proteins are referred to, it should be understoodthat assays may make use of the mature protein, lacking the signalsequence.

EC₅₀ values may be used as a numerical measure of agonist potency at agiven receptor. An EC₅₀ value is a measure of the concentration of acompound required to achieve half of that compound's maximal activity ina particular assay. Thus, for example, a compound having EC₅₀ [hCTR2]lower than the EC₅₀ [hCTR2] of native amylin, or lower than that ofpramlintide, in a particular assay may be considered to have higherpotency or activity at the receptor than amylin, or higher than that ofpramlintide, respectively.

In some embodiments of compounds of the present invention, the EC₅₀towards hCTR2 is below 1.4 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hCTR2 is below 0.8 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hCTR2 is below 0.4 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hCTR2 is below 0.2 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hCTR2 is below 0.1 nM.

An EC₅₀ towards hCTR2 of approximately 0.2 (+/−10%) or below may bedesirable. The EC₅₀ at hCTR2 may be an indication of the effect of acompound on food intake, weight gain and/or weight loss. Compounds withlower EC₅₀ values at hCTR2 may have a greater effect on theseparameters.

In some embodiments of compounds of the present invention, the EC₅₀towards hAMYR3 is below 1 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hAMYR3 is below 0.5 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hAMYR3 is below 0.4 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hAMYR3 is below 0.3 nM.

In some embodiments of compounds of the present invention, the EC₅₀towards hAMYR3 is below 0.2 nM.

For example, the EC₅₀ at hCTR2 (when expressed in the absence of hRAMP1,hRAMP2 and hRAMP3) may be less than 10-fold lower than the EC₅₀ at anyor all of hAMYR1, hAMYR2 and hAMYR3, e.g. at hAMYR3.

The EC₅₀ at hCTR2 (when expressed in the absence of hRAMP1, hRAMP2 andhRAMP3) may be less than 5-fold lower than the EC₅₀ at any or all ofhAMYR1, hAMYR2 and hAMYR3, e.g. at hAMYR3.

The EC₅₀ at hCTR2 (when expressed in the absence of hRAMP1, hRAMP2 andhRAMP3) may be substantially equal to (e.g. +/−50%) the EC₅₀ at any orall of hAMYR1, hAMYR2 and hAMYR3, e.g. at hAMYR3.

The EC₅₀ at hCTR2 (when expressed in the absence of hRAMP1, hRAMP2 andhRAMP3) may be higher than the EC₅₀ at any or all of hAMYR1, hAMYR2 andhAMYR3, e.g. at hAMYR3.

Such assays may be performed under the conditions described in Examples2 and 3.

Additionally or alternatively, compounds of the invention may showexcellent solubility. For example, they may show solubility of greaterthan or equal to 1 mg/ml at pH 4, pH 5, pH 6, pH 7 and/or pH 7.5, e.g.at 25° C., e.g. under the conditions described in Example 4.

Additionally or alternatively, compounds of the invention may showexcellent resistance to fibrillation. For example, they may show nodetectable fibrillation after 96 hours at pH 4.0 and/or pH 7.0, e.g. at40° C., e.g. under the conditions described in Example 5.

Additionally or alternatively, compounds of the invention may showexcellent chemical stability, i.e. resistance to degradation insolution. For example, they may retain at least 70% purity, at least 75%purity, at least 80% purity, at least 85% purity, at least 90% purity,or at least 95% purity after incubation at pH 4, pH 7.5, and/or pH 9 at40° C. for 7 days, e.g. under the conditions described in Example 6.

Therapeutic Uses

The compounds of the invention are useful, inter alia, in the reductionof food intake, promotion of weight loss, and inhibition or reduction ofweight gain. They may therefore provide an attractive treatment optionfor, inter alia, obesity and metabolic diseases caused, characterisedby, or associated with, excess body weight.

Thus, the compounds may be used in a method of treating, inhibiting orreducing weight gain, promoting weight loss, reducing food intake,and/or reducing excess body weight. Treatment may be achieved, forexample, by control of appetite, feeding, food intake, calorie intakeand/or energy expenditure.

The compounds may be used in a method of treating obesity as well asassociated diseases, disorders and health conditions, including, but notlimited to, morbid obesity, obesity prior to surgery, obesity-linkedinflammation, obesity-linked gallbladder disease and obesity-inducedsleep apnea and respiratory problems, degeneration of cartilage,osteoarthritis, and reproductive health complications of obesity oroverweight such as infertility.

The compounds may also be used in in a method of prevention or treatmentof Alzheimer's disease, diabetes, type 1 diabetes, type 2 diabetes,pre-diabetes, insulin resistance syndrome, impaired glucose tolerance(IGT), disease states associated with elevated blood glucose levels,metabolic disease including metabolic syndrome, hyperglycemia,hypertension, atherogenic dyslipidemia, hepatic steatosis (“fattyliver”; including non-alcoholic fatty liver disease (NAFLD), whichitself includes non-alcoholic steatohepatitis (NASH)), kidney failure,arteriosclerosis (e.g. atherosclerosis), macrovascular disease,microvascular disease, diabetic heart (including diabetic cardiomyopathyand heart failure as a diabetic complication) coronary heart disease,peripheral artery disease or stroke.

The compounds may also be useful in lowering circulating LDL levelsand/or increasing HDL/LDL ratio.

The effects of the compounds described above may be mediated in whole orin part via an effect on body weight, or may be independent thereof.

Metabolic syndrome is characterized by a group of metabolic risk factorsin one person. They include abdominal obesity (excessive fat tissuearound the abdominal internal organs), atherogenic dyslipidemia (bloodfat disorders including high triglycerides, low HDL cholesterol and/orhigh LDL cholesterol, which foster plaque buildup in artery walls),elevated blood pressure (hypertension), insulin resistance and glucoseintolerance, prothrombotic state (e.g. high fibrinogen or plasminogenactivator inhibitor-1 in the blood), and proinflammatory state (e.g.,elevated C-reactive protein in the blood).

Individuals with metabolic syndrome are at increased risk of coronaryheart disease and other diseases related to other manifestations ofarteriosclerosis (e.g. stroke and peripheral vascular disease). Thedominant underlying risk factor for this syndrome appears to beabdominal obesity.

Pharmaceutical Compositions

The invention also extends to compositions, such as pharmaceuticalcompositions, comprising amylin analogues. As with all aspects of theinvention, it is to be understood that reference to an amylin analogueencompasses reference to pharmaceutically acceptable salts and solvates.

The amylin analogues of the present invention may be formulated aspharmaceutical compositions which are suited for administration with orwithout storage, and which typically comprise a therapeuticallyeffective amount of at least one peptide of the invention, together witha pharmaceutically acceptable carrier, excipient or vehicle.

The term “pharmaceutically acceptable carrier” includes any of thestandard pharmaceutical carriers. Pharmaceutically acceptable carriersfor therapeutic use are well known in the pharmaceutical art and aredescribed, for example, in “Remington's Pharmaceutical Sciences”, 17thedition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa.,USA, 1985. For example, sterile saline and phosphate-buffered saline atslightly acidic or physiological pH may be used. Suitable pH-bufferingagents may, e.g., be phosphate, citrate, acetate,tris(hydroxymethyl)aminomethane (TRIS),N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), ammoniumbicarbonate, diethanolamine, histidine, arginine, lysine or acetate(e.g. as sodium acetate), or mixtures thereof. The term furtherencompasses any carrier agents listed in the US Pharmacopeia for use inanimals, including humans.

A pharmaceutical composition of the invention may be in unit dosageform. In such form, the composition is divided into unit dosescontaining appropriate quantities of the active component or components.The unit dosage form may be presented as a packaged preparation, thepackage containing discrete quantities of the preparation, for example,packaged tablets, capsules or powders in vials or ampoules. The unitdosage form may also be, e.g., a capsule, cachet or tablet in itself, orit may be an appropriate number of any of these packaged forms. A unitdosage form may also be provided in single-dose injectable form, forexample in the form of a pen device containing a liquid-phase (typicallyaqueous) composition. Compositions may be formulated for any suitableroute and means of administration. Pharmaceutically acceptable carriersor diluents include those used in formulations suitable for e.g. oral,intravitreal, rectal, vaginal, nasal, topical, enteral or parenteral(including subcutaneous (sc), intramuscular (im), intravenous (iv),intradermal and transdermal) administration or administration byinhalation. The formulations may conveniently be presented in unitdosage form and may be prepared by any of the methods well known in theart of pharmaceutical formulation.

Subcutaneous or transdermal modes of administration may in some cases besuitable for peptides of the invention.

Further embodiments relate to devices, dosage forms and packages used todeliver the pharmaceutical formulations of the present invention. Thus,at least one peptide in a stable or preserved formulation or solutiondescribed herein can be administered to a patient in accordance with thepresent invention via a variety of delivery methods, including by sc orim injection, or by transdermal, pulmonary or transmucosaladministration, or by implant, or by use of an osmotic pump, cartridge,micro-pump or other means recognized by a person of skill in the art.

Still further embodiments relate to oral formulations and oraladministration. Formulations for oral administration may rely on theco-administration of adjuvants (e.g. resorcinols and/or nonionicsurfactants such as polyoxyethylene oleyl ether andn-hexadecylpolyethylene ether) to artificially increase the permeabilityof the intestinal walls, and/or the co-administration of enzymaticinhibitors (e.g. pancreatic trypsin inhibitors,diisopropylfluorophosphate (DFF) or trasylol) to inhibit enzymaticdegradation. The active constituent compound of a solid-type dosage formfor oral administration can be mixed with at least one additive, such assucrose, lactose, cellulose, mannitol, trehalose, raffinose, maltitol,dextran, starches, agar, alginates, chitins, chitosans, pectins, gumtragacanth, gum arabic, gelatin, collagen, casein, albumin, synthetic orsemisynthetic polymer, or glyceride. These dosage forms can also containother type(s) of additives, e.g. an inactive diluting agent, a lubricant(such as magnesium stearate), a paraben, a preserving agent (such assorbic acid, ascorbic acid or alpha-tocopherol), an antioxidant (such ascysteine), a disintegrant, binder, thickener, buffering agent,pH-adjusting agent, sweetening agent, flavoring agent or perfumingagent.

Dosages

A typical dosage of an amylin analogue as employed in the context of thepresent invention may be in the range from about 0.0001 to about 100mg/kg body weight per day, such as from about 0.0005 to about 50 mg/kgbody weight per day, such as from about 0.001 to about 10 mg/kg bodyweight per day, e.g. from about 0.01 to about 1 mg/kg body weight perday, administered in one or more doses, such as from one to three doses.The exact dosage employed will depend, inter alia, on: the nature andseverity of the disease or disorder to be treated, on the sex, age, bodyweight and general condition of the subject to be treated, on possibleother, concomitant, disease or disorder that is undergoing or is toundergo treatment, as well as on other factors that will be known to amedical practitioner of skill in the art.

An amylin analogue of the invention may be administered continuously(e.g. by intravenous administration or another continuous drugadministration method), or may be administered to a subject atintervals, typically at regular time intervals, depending on the desireddosage and the pharmaceutical composition selected by the skilledpractitioner for the particular subject. Regular administration dosingintervals include, e.g., once daily, twice daily, once every two, three,four, five or six days, once or twice weekly, once or twice monthly, andthe like. Such regular peptide administration regimens may, in certaincircumstances such as, e.g., during chronic long-term administration, beadvantageously interrupted for a period of time so that the medicatedsubject reduces the level of, or stops taking, the medication, oftenreferred to as taking a “drug holiday.” Drug holidays are useful for,e.g., maintaining or regaining sensitivity to a drug especially duringlong-term chronic treatment, or to reduce unwanted side-effects oflong-term chronic treatment of the subject with the drug. The timing ofa drug holiday depends on the timing of the regular dosing regimen andthe purpose for taking the drug holiday (e.g., to regain drugsensitivity and/or to reduce unwanted side effects of continuous,long-term administration). In some embodiments, the drug holiday may bea reduction in the dosage of the drug (e.g. to below the therapeuticallyeffective amount for a certain interval of time). In other embodiments,administration of the drug is stopped for a certain interval of timebefore administration is started again using the same or a differentdosing regimen (e.g. at a lower or higher dose and/or frequency ofadministration). A drug holiday of the invention may thus be selectedfrom a wide range of time-periods and dosage regimens. An exemplary drugholiday is two or more days, one or more weeks, or one or more months,up to about 24 months of drug holiday. So, for example, a regular dailydosing regimen with a peptide of the invention may, for example, beinterrupted by a drug holiday of a week, or two weeks, or four weeks,after which time the preceding, regular dosage regimen (e.g. a daily ora weekly dosing regimen) is resumed. A variety of other drug holidayregimens are envisioned to be useful for administering peptides of theinvention.

Thus, the peptide may be delivered via an administration regime whichcomprises two or more administration phases separated by respective drugholiday phases.

During each administration phase, the peptide is administered to therecipient subject in a therapeutically effective amount according to apre-determined administration pattern. The administration pattern maycomprise continuous administration of the drug to the recipient subjectover the duration of the administration phase. Alternatively, theadministration pattern may comprise administration of a plurality ofdoses of the peptide to the recipient subject, wherein said doses arespaced by dosing intervals.

A dosing pattern may comprise at least two doses per administrationphase, at least five doses per administration phase, at least 10 dosesper administration phase, at least 20 doses per administration phase, atleast 30 doses per administration phase, or more.

Said dosing intervals may be regular dosing intervals, which may be asset out above, including once daily, twice daily, once every two, three,four, five or six days, once or twice weekly, once or twice monthly, ora regular and even less frequent dosing interval, depending on theparticular dosage formulation, bioavailability, and pharmacokineticprofile of the peptide.

An administration phase may have a duration of at least two days, atleast a week, at least 2 weeks, at least 4 weeks, at least a month, atleast 2 months, at least 3 months, at least 6 months, or more.

Where an administration pattern comprises a plurality of doses, theduration of a possible following drug holiday phase is longer than thedosing interval used in that administration pattern. Where the dosinginterval is irregular, the duration of a drug holiday phase may begreater than the mean interval between doses over the course of theadministration phase. Alternatively the duration of the drug holiday maybe longer than the longest interval between consecutive doses during theadministration phase.

The duration of a possible drug holiday phase may be at least twice thatof the relevant dosing interval (or mean thereof), at least 3 times, atleast 4 times, at least 5 times, at least 10 times, or at least 20 timesthat of the relevant dosing interval or mean thereof.

Within these constraints, a drug holiday phase may have a duration of atleast two days, at least a week, at least 2 weeks, at least 4 weeks, atleast a month, at least 2 months, at least 3 months, at least 6 months,or more, depending on the administration pattern during the previousadministration phase.

An administration regime entailing the use of drug holiday comprises atleast 2 administration phases. Consecutive administration phases areseparated by respective drug holiday phases. Thus the administrationregime may comprise at least 3, at least 4, at least 5, at least 10, atleast 15, at least 20, at least 25, or at least 30 administrationphases, or more, each separated by respective drug holiday phases.

Consecutive administration phases may utilise the same administrationpattern, although this may not always be desirable or necessary.However, if other drugs or active agents are administered in combinationwith a peptide of the invention, then typically the same combination ofdrugs or active agents is given in consecutive administration phases. Incertain embodiments, the recipient subject is a human.

Combination Therapy

An amylin analogue of the invention may be administered as part of acombination therapy together with another active agent for the treatmentof the disease or disorder in question, e.g. an anti-diabetic agent, ananti-obesity agent, an agent for treatment of metabolic syndrome, ananti-dyslipidemia agent, an anti-hypertensive agent, a proton pumpinhibitor, or an anti-inflammatory agent. In such cases, the two activeagents may be given together or separately, e.g. as constituents in thesame pharmaceutical composition or formulation, or as separateformulations.

Thus a peptide of the invention may have some benefit if administered incombination with an anti-diabetic agent of known type, including, butnot limited to, metformin, a sulfonylurea, a glinide, a DPP-IVinhibitor, a glitazone, a GLP-1 receptor agonist (including GLP-1 or aGLP-1 analogue, an exendin-4 or an exendin-4 analogue, any other GLP-1receptor agonist including liraglutide (Saxenda™, Victoza™), Dulaglutideor Albiglutide or a glucagon-GLP-1 dual agonist, e.g. as described inWO2008/101017, WO2008/152403, WO2010/070252, WO2010/070253,WO2010/070255, WO2010/070251, WO2011/006497, WO2011/160630,WO2011/160633, WO2013/092703, WO2014/041195), an SGLT2 inhibitor (i.e.an inhibitor of sodium-glucose transport, e.g. a gliflozin such asempagliflozin, canagliflozin, dapagliflozin or ipragliflozin), a GPR40agonist (FFAR1/FFA1 agonist, e.g. fasiglifam), or an insulin or aninsulin analogue. Examples of appropriate insulin analogues include, butare not limited to, Lantus™, Novorapid™, Humalog™, Novomix™, Actraphane™HM, Levemir™ Degludec™ and Apidra™. Other relevant anti-diabetic agentsin this connection include GLP-1 receptor agonists, such as exenatide(Byetta™ and Bydureon™ exendin-4) and Byetta LAR™, lixisenatide(Lyxumia™) and liraglutide (Victoza™).

Moreover, a peptide of the invention may be used in combination with ananti-obesity agent of known type, including, but not limited to, peptideYY or an analogue thereof, neuropeptide Y (NPY) or an analogue thereof,a cannabinoid receptor 1 antagonist, a lipase inhibitor, Human prolsletPeptide (HIP), a melanocortin receptor 4 agonist, a GLP-1 receptoragonist (including GLP-1 or a GLP-1 analogue, an exendin-4 or anexendin-4 analogue, any other GLP-1 receptor agonist includingliraglutide (Saxenda™, Victoza™), Dulaglutide or Albiglutide or aglucagon-GLP-1 dual agonist, e.g. as described in WO2008/101017,WO2008/152403, WO2010/070252, WO2010/070253, WO2010/070255,WO2010/070251, WO2011/006497, WO2011/160630, WO2011/160633,WO2013/092703, WO2014/041195), Orlistat™ Sibutramine™, phentermine, amelanin concentrating hormone receptor 1 antagonist, CCK, amylin,pramlintide and leptin, as well as analogues thereof.

A peptide of the invention may further be used in combination with ananti-hypertension agent of a known type, including, but not limited to,an angiotensin-converting enzyme inhibitor, an angiotensin II receptorblocker, a diuretic, a beta-blocker and a calcium channel blocker.

A peptide of the invention may still further be used in combination withan anti-dyslipidemia agent of known type, including, but not limited to,a statin, a fibrate, a niacin, a PSCK9 (Proprotein convertasesubtilisin/kexin type 9) inhibitor, and a cholesterol absorptioninhibitor.

A peptide of the invention may also be used in combination with a protonpump inhibitor (i.e. a pharmaceutical agent possessing pharmacologicalactivity as an inhibitor of H⁺/K⁺-ATPase) of known type, including, butnot limited to, an agent of the benzimidazole derivative type or of theimidazopyridine derivative type, such as Omeprazole™, Lansoprazole™,Dexlansoprazole™, Esomeprazole™, Pantoprazole™, Rabeprazole™, Zolpidem™,Alpidem™, Saripidem™ or Necopidem™.

In addition, with regard to anti-inflammatory treatment, a peptide ofthe invention may be beneficial if administered in combination with ananti-inflammatory agent of known type, including, but not limited to:

steroids and corticosteroids, such as beclomethasone,methylprednisolone, betamethasone, prednisone, dexamethasone, andhydrocortisone;non-steroidal anti-inflammatory agents (NSAIDs), such as propionic acidderivatives (e.g. alminoprofen, benoxaprofen, bucloxic acid, carprofen,fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen,ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen,suprofen, tiaprofenic acid and tioxaprofen); acetic acid derivatives(e.g. indomethacin, acemetacin, alclofenac, clidanac, diclofenac,fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac,oxpinac, sulindac, tiopinac, tolmetin, zidometacin and zomepirac);fenamic acid derivatives (e.g. flufenamic acid, meclofenamic acid,mefenamic acid, niflumic acid and tolfenamic acid); biphenylcarboxylicacid derivatives (e.g. diflunisal and flufenisal); oxicams (e.g.isoxicam, piroxicam, sudoxicam and tenoxicam); salicylates (e.g.acetylsalicylic acid and sulfasalazine); and pyrazolones (e.g. apazone,bezpiperylon, feprazone, mofebutazone, oxyphenbutazone andphenylbutazone);COX II inhibitors, such as rofecoxib and celecoxib; preparations ofinterferon beta (e.g. interferon beta-1a or interferon beta-1b);and certain other compounds, such as 5-aminosalicylic acid and prodrugsand pharmaceutically acceptable salts thereof.

Metformin has also been demonstrated to have anti-inflammatoryproperties (see, e.g., Haffner et al., Diabetes 54: 1566-1572 (2005))and as such may also be useful in combination with compounds (peptides)of the invention.

Devices and Kits

In some embodiments, the invention relates to a device comprising anamylin analogue or pharmaceutical composition of the invention, fordelivery of the analogue to a subject. Via such devices, amylinanalogues can be administered to a patient via a variety of deliverymethods, including: intravenous, subcutaneous, intramuscular orintraperitoneal injection; oral administration; transdermaladministration; pulmonary or transmucosal administration; administrationby implant, osmotic pump, cartridge or micro pump; or by other meansrecognized by a person of skill in the art.

In some embodiments, the invention relates to a kit comprising an amylinanalogue of the invention or a pharmaceutical composition of theinvention. In certain embodiments, the kit further comprises packagingand/or instructions for use.

The device or kit may be useful for combination therapy as describedabove. Thus the device or kit may further comprise a further activeagent, e.g. an anti-diabetic agent, an anti-obesity agent, an agent fortreatment of metabolic syndrome, an anti-dyslipidemia agent, ananti-hypertensive agent, a proton pump inhibitor, or ananti-inflammatory agent as described above, or a pharmaceuticalcomposition comprising such an active agent.

EXAMPLES

The following examples demonstrate certain specific embodiments of thepresent invention. The following examples were carried out usingstandard techniques that are well known and routine to those of skill inthe art, except where otherwise described in detail. It is to beunderstood that these examples are for illustrative purposes only and donot purport to be wholly definitive as to conditions or scope of theinvention. As such, they should not be construed as limiting the scopeof the present invention in any way.

Abbreviations employed in the examples include:

-   Acm: acetaminomethyl-   COMU™:    (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbeniumhexafluorophosphate-   DCM: dichloromethane-   DMF: N,N-dimethylformamide-   HATU: 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium    hexafluorophosphate-   DIPEA: diisopropylethylamine-   DODT: 3,6-dioxa-1,8-octanedithiol-   EtOH: ethanol-   Et₂O: diethyl ether-   TFA: trifluoroacetic acid-   TIS: triisopropylsilane-   MeCN: acetonitrile-   HPLC: high performance liquid chromatography-   RP-HPLC: reverse phase high performance liquid chromatography-   MS: mass spectrometry-   ESI-MS: electron spray ionization mass spectrometry-   IBMX: 3-isobutyl-1-methylxanthine-   BSA: bovine serum albumin-   cAMP: cyclic adenosine monophosphate-   DMEM: Dulbecco's Modified Eagle Medium-   FCS: fetal calf serum-   HEPES: N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid-   p-ERK: phosphorylated extracellular regulated kinase-   PBS: phosphate-buffered saline-   Boc: tert-butoxycarbonyl-   Fmoc: 9-fluorenylmethoxycarbonyl-   Trt: trityl (i.e. triphenylmethyl)-   NEP: N-ethylpyrrolidone-   NMP N-methylpyrrolidone-   v/v: volume/volume-   w/v: weight/volume

The following examples are provided to illustrate certain embodiments ofthe invention and are not intended to limit the scope of the invention.

Measurement of Physiological Parameters

Unless otherwise specified, whole-blood glucose levels were determinedon tail-vein blood samples by the Biosen (EKF Diagnostic, Germany)enzyme-based electrode method. Blood samples were analyzed for glycatedhemoglobin (HbA1c) using a Cobas c111 analyzer (Roche Diagnostics,Mannheim, Germany). Plasma insulin levels were measured using a MesoScale Discovery (MSD) system (Rockville, Md., USA). Liver fat contentwas determined by magnetic resonance (MR) scanning using an Echo systemsMR scanner. Fat depots were measured by weighing of excised fat.

Example 1: Synthesis of Compounds

The following compounds were synthesised:

(SEQ ID NO: 102)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 1) (SEQ ID NO: 103)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd.2) (SEQ ID NO: 104)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 3) (SEQ ID NO: 105)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂(Compd. 4) (SEQ ID NO: 106)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSINVGSNT-Apr-NH₂(Compd. 5) (SEQ ID NO: 107)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 6) (SEQ ID NO: 108)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 7) (SEQ ID NO: 109)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 8) (SEQ ID NO: 110)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 9) (SEQ ID NO: 111)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 10) (SEQ ID NO: 112)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(Compd. 11) (SEQ ID NO: 113)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 12) (SEQ ID NO: 114)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 13) (SEQ ID NO: 115)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 14) (SEQ ID NO: 116)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 15) (SEQ ID NO: 117)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 16). (SEQ ID NO: 118)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLANFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 17) (SEQ ID NO: 119)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 18) (SEQ ID NO: 120)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 19) (SEQ ID NO: 121)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRSVF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 20) (SEQ ID NO: 122)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 21) (SEQ ID NO: 123)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 22) (SEQ ID NO: 124)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂(Compd. 23) (SEQ ID NO: 125)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 24) (SEQ ID NO: 126)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNTP-NH₂(Compd. 25) (SEQ ID NO: 127)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂(Compd. 26) (SEQ ID NO: 128)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂(Compd. 27) (SEQ ID NO: 129)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 28) (SEQ ID NO: 130)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 29) SEQ ID NO: 131)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 30) (SEQ ID NO: 132)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 31) (SEQ ID NO: 133)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 32) (SEQ ID NO: 134)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 33) (SEQ ID NO: 135)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 34) (SEQ ID NO: 136)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 35) (SEQ ID NO: 137)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 36) (SEQ ID NO: 138)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 37) (SEQ ID NO: 139)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 38) (SEQ ID NO: 140)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂(Compd. 39) (SEQ ID NO: 141)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂(Compd. 40) (SEQ ID NO: 142)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 41) (SEQ ID NO: 143)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂(Compd. 42) (SEQ ID NO: 144)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 43) (SEQ ID NO: 145)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(Compd. 44) (SEQ ID NO: 146)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Apr-NH₂(Compd. 45) (SEQ ID NO: 147)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 46) (SEQ ID NO: 148)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-TP-NH₂(Compd. 47) (SEQ ID NO: 149)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 48) (SEQ ID NO: 150)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 49) (SEQ ID NO: 151)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 50) (SEQ ID NO: 152)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂(Compd. 51) (SEQ ID NO: 153)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 52) (SEQ ID NO: 154)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 53) (SEQ ID NO: 155)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 54) (SEQ ID NO: 156)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 55) (SEQ ID NO: 157)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 56) (SEQ ID NO: 158)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 57) (SEQ ID NO: 159)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 58) (SEQ ID NO: 160)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNT-Hyp-NH₂(Compd. 59) (SEQ ID NO: 161)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSDT-Hyp-NH₂(Compd. 60) (SEQ ID NO: 162)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 61) (SEQ ID NO: 163)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 62) (SEQ ID NO: 164)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 63) (SEQ ID NO: 165)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 64) (SEQ ID NO: 166)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 65) (SEQ ID NO: 167)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 66) (SEQ ID NO: 168)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 67) (SEQ ID NO: 169)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 68) (SEQ ID NO: 170)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 69) (SEQ ID NO: 171)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 70) (SEQ ID NO: 172)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 71) (SEQ ID NO: 173)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 72) (SEQ ID NO: 174)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 73) (SEQ ID NO: 175)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 74) (SEQ ID NO: 176)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 75) (SEQ ID NO: 177)[19CD]-isoGlu-R-C( )-PTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂(Compd. 76) (SEQ ID NO: 178)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 77) (SEQ ID NO: 179)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 78) (SEQ ID NO: 180)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 79) (SEQ ID NO: 181)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂(Compd. 80) (SEQ ID NO: 182)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 81) (SEQ ID NO: 183)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTTP-NH₂(Compd. 82) (SEQ ID NO: 184)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂(Compd. 83) (SEQ ID NO: 185)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 84) (SEQ ID NO: 186)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂(Compd. 85) (SEQ ID NO: 187)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 86) (SEQ ID NO: 188)[19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂(Compd. 87) (SEQ ID NO: 189)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 88) (SEQ ID NO: 190)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 89) (SEQ ID NO: 191)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 90) (SEQ ID NO: 192)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂(Compd. 91) (SEQ ID NO: 193)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 92) (SEQ ID NO: 194)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 93) (SEQ ID NO: 195)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂(Compd. 94) (SEQ ID NO: 196)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂(Compd. 95) (SEQ ID NO: 197)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂(Compd. 96)([19CD]-isoGlu represents a [19-carboxynonadecanoyl] group linked to thefree alpha-amino group of the N-arginine residue via an iso-glutamicacid linker.)

Also synthesized, for use as controls, were:

Pramlintide: (SEQ ID NO: 198)H-K( )NTATC( )ATQRLANFLVHSSNNFGPILPPINVGSNTY-NH₂NN96: N-α-[(S)-4-carboxy-4-(19-carboxynonadecanoylamino)butyryl]-[Arg1,Glu14, His17, Pro37]-pramlintide-NH₂(NN96 is disclosed in WO 2012/168430 and has the amino acid sequence:

(SEQ ID NO: 199) RC( )NTATC( )ATQRLAEFLHHSSNNFGPILPPTNVGSNTP)(SEQ ID NO: 200) [19CD]-isoGlu-R-C( )-NTAT-C( )-ATQRLAEFLHHSSFGPILPFINVGSNTP-NH₂ (Compd. 97) (SEQ ID NO: 201)[19CD]-isoGlu-R-C( )-GTAT-C( )-ATERLA-Aad-FLQRSSNNF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂ (Compd. 98)(SEQ ID NO: 202) [19CD]-isoGlu-R-C( )-QTAT-C( )-ATERLAHFLQRSSNNF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂ (Compd. 99) (SEQ ID NO: 203)[19CD]-isoGlu-R-C( )-QTAT-C( )-ATDRLA-Aad-FLQRSSNNF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂ (Compd. 100)

Compound 97 has the same sequence as NN96 except for a deletion of theAsn residues at positions 21 and 22.

Compounds 98, 99 and 100 have the same sequences as compound 55,compound 57 and compound 89 respectively, except for Asn residuesinserted at positions 21 and 22.

Parentheses “( )” indicate intramolecular disulphide bridges between theside chains of cysteine residues at positions 2 and 7 of the relevantamino acid sequences.

Unless otherwise specified, reagents and solvents employed in thefollowing were available commercially in standard laboratory reagent oranalytical grade, and were used without further purification.

Suitable general procedures for synthesis include the following:

General Procedures for Solid-Phase Synthesis of Peptides

A CEM Liberty Peptide Synthesizer was employed, using standard Fmocchemistry. TentaGel™ S Ram resin (1 g; 0.25 mmol/g) was swelled in DMF(10 ml) prior to use and transferred between tube and reaction vesselusing DCM and DMF. Pseudoprolines [i.e. dipeptides employed to minimizeaggregation during peptide synthesis, such asFmoc-Phe-Thr(ψ-Me,Me-Pro)-OH and Fmoc-Asp-Ser(ψ-Me,Me-Pro)-OH andFmoc-Ser-Ser(ψ-Me,Me-Pro)-OH] were used where appropriate, andnon-naturally occurring amino acids and other suitable building blockswere employed without any changes to the general procedure.

The following optical isomers of particular amino acids (includingnon-naturally occurring amino acids) were employed in the synthesis ofthe compounds:

Apr: (2S,4R)-4-aminoproline [also denoted (4R)-4-amino-L-proline];Hyp: (2S,4R)-4-hydroxyproline [also denoted (4R)-4-hydroxy-L-proline].Aad: (2S)-2-aminoadipic acid

Coupling:

An Fmoc-amino acid in DMF/DCM (2:1; 0.2 M; 5 ml) was added to the resinin a CEM Discover microwave unit together with COMU/DMF (0.5 M; 2 ml)and DIPEA/DMF (2.0 M; 1 ml). The coupling mixture was heated to 75° C.for 5 min. while nitrogen was bubbled through the mixture. The resin wasthen washed with DMF (4×10 ml). Alternatively the coupling was donewithout heating and the reaction time extended to 60 min in this case.

In the case of difficult couplings (e.g. coupling of a residueimmediately after an N-methylated amino acid residue or other stericallyhindered amino acid residue as recognized by a person of skill in theart) the coupling was repeated one or more times.

Deprotection:

Piperidine/DMF (1:4, i.e. 1 part piperidine to 4 parts DMF by volume; 10ml) was added to the resin for initial deprotection, and the mixture wasmicrowave-heated (40° C.; 30 sec.). The reaction vessel was drained anda second portion of piperidine/DMF (1:4; 10 ml) was added and heated(75° C.; 3 min) again. The resin was then washed with DMF (6×10 ml).

Oxidative Cyclisation

Intramolecular ring formation (disulfide bridge formation) between theCys residues in positions 2 and 7 (initially coupled in the form ofAcm-protected cysteines) was performed with the peptide still attachedto the resin, using 163 mg thallium(III) trifluoroacetate [TI(TFA)₃] in5 mL NMP in a simultaneous Acm-deprotection and disulfide-formationstep.

Cleavage:

The resin was washed with EtOH (3×10 ml) and Et₂O (3×10 ml) and dried toconstant weight at room temperature (r.t.). The crude peptide wascleaved from the resin by treatment with TFA/TIS/H₂O (90:5:5; 40 ml; 2h; room temp.) or alternatively with TFA/DODT (95:5; 40 ml; 2 h; roomtemp.). Most of the TFA was removed under reduced pressure, and thecrude peptide was precipitated and washed three times with Et₂O anddried to constant weight at room temperature.

Purification and Characterisation:

The crude peptide was purified by preparative reverse phase HPLC using aPerSeptive Biosystems VISION Workstation or a Gilson system (Pumps:“Pump 305”, “331 Pump”, “332 Pump”, “402 Syringe Pump”; column changer“Valvemate® II” UV detector “UV/Vis-155”; and the fraction collector “GX281” equipped with a suitable column and a fraction collector, and runwith a gradient of buffer A (0.1% aqueous TFA) and buffer B (0.1% TFA,90% MeCN, water). Fractions were analysed by analytical HPLC and MS, andrelevant fractions were pooled and lyophilised. The final product wascharacterized by HPLC and MS.

One of skill in the art will appreciate that standard methods of peptidesynthesis may be used to generate the compounds of the invention.

Example 2: Generation of Cell Lines Expressing (i) Human CalcitoninReceptor (hCTR2), and (ii) Human Amylin Receptor 3 (hAMYR3) Consistingof hCTR2 Co-Expressed with Human Receptor Activity Modifying Protein 3(hRAMP3)

The cell line COS7, originating from African Green Monkey kidneyfibroblast cells, was used for establishment of the stable cell linesdescribed below. The COS7 cellular background was used due to it beingRAMP naïve, and as such it provides the best available system fortesting of the monomeric hCTR and different heterodimeric amylinreceptor subtypes functionally generated by introduction of theindividual RAMPs.

Calcitonin Receptor Cell Line:

A cell line expressing the human calcitonin receptor (hCTR2) wasgenerated in the COS7 cellular background as stable clones. In brief,hCTR2 (GI: 4502547) was amplified by PCR using primers encoding terminalrestriction sites for subcloning. The 5′-end primers additionallyencoded a near Kozak consensus sequence to ensure efficient translation.The fidelity of the DNA encoding the receptor was confirmed by DNAsequencing. The PCR products encoding the receptor were subcloned into amammalian expression vector containing a neomycin (G418) resistancemarker. The mammalian expression vector encoding the receptor wastransfected into COS7 cells by a standard liposome transfection method.48 hours post-transfection, cells were seeded for limited dilutioncloning and selected with 1 mg/ml G418 in the culture medium. After 3weeks, surviving colonies of hCTR2-expressing cells were picked,propagated and tested in the amylin efficacy assay as described inExample 3 below. One hCTR2-expressing clone was chosen for compoundprofiling.

Amylin Receptor Cell Line:

A cell line expressing the human amylin receptor 3 (hAMYR3) wasgenerated in the COS7 cellular background as stable clones. In brief,hCTR2 (GI:4502547) and hRAMP3 (GI:118572586) were amplified by PCR usingprimers encoding terminal restriction sites for subcloning. The 5′-endprimers additionally encoded a near Kozak consensus sequence to ensureefficient translation. The fidelity of the DNA encoding the receptor wasconfirmed by DNA sequencing. The PCR products encoding the receptor weresubcloned into a proprietary tri-cistronic mammalian expression vectorwith RAMP3, hCTR2 and neomycin (G418) resistance marker. The mammalianexpression vector encoding the receptor was transfected into COS7 cellsby a standard liposome transfection method. 48 hours post-transfection,cells were seeded for limited dilution cloning and selected with 1 mg/mlG418 in the culture medium. After 3 weeks, surviving colonies ofhAMY3R-expressing cells were picked, propagated and tested in the amylinefficacy assay as described in Example 3 below. The functionalgeneration of the amylin receptor phenotype was verified in the efficacyassay by a left-shifted efficacy response to amylin relative tomonomeric calcitonin receptor, and one hAMYR3-expressing clone waschosen for compound profiling.

Example 3: hCTR2 and hAMYR3 Assays

In vitro activity of test peptides at the hCTR2 and hAMYR3 receptors wasassessed by measuring the induction of cAMP following stimulation of thereceptor using the AlphaScreen® cAMP Assay kit from Perkin-Elmer.

Briefly, COS7 cells expressing hCTR2 (see Example 2, above) were seededat 30-40,000 cells per well in 96-well microtiter plates coated with0.01% poly-L-lysine, and grown for 1 day in culture in 100 μl growthmedium [DMEM, 10% FCS, Penicillin (100 IU/ml), Streptomycin (100μg/ml)]. On the day of analysis, growth medium was removed and the cellswere washed once with 200 μl Tyrode buffer [Tyrode's Salts (9.6 g/I), 10mM HEPES, pH 7.4]. Cells were incubated in 100 μl Tyrode buffercontaining increasing concentrations of test peptides, 100 M IBMX and0.1% casein for 15 min at 37° C. The reaction was stopped by carefullydecanting off the compound/buffer medium and replacing it withlysis/detection buffer (80 μl 0.1% w/v BSA, 5 mM HEPES, 0.3% v/vTween-20 in deionized water). After incubation at room temperature for10 min., the cAMP content of the resulting cell lysate was estimatedaccording to the AlphaScreen® cAMP Assay manufacturer's instructions.EC₅₀ values were estimated by computer-aided curve fitting using the4-parameter logistic (4PL) non-linear model.

The in vitro activity results (expressed as EC₅₀ values) are summarizedin Table 1, below.

Example 4: Assessment of Solubility

A stock solution of the test peptide (2 mg/ml; determined from theweighed amount of peptide) in demineralized water adjusted to pH 2.5with HCl was prepared, and aliquots were diluted 1:1 in 100 mM acetatebuffer (pH 4.0 and pH 5.0), 100 mM histidine buffer (pH 6.0 and pH 7.0)and 100 mM phosphate buffer (pH 6.0, pH 7.0 and pH7.5), respectively,and loaded in a standard flat-bottom, non-sterile 96-well UV Microplate.The absorbance of samples (single samples, n=1) at 280 and 325 nm wasmeasured in an absorbance-based plate reader, which was preheated toambient temperature (typically 25° C.). The turbidity absorbancecriterion for a peptide solubility of ≥1 mg/ml was an absorbance at 325nm of s 0.02 absorbance units (which is 5 to 6 times the standarddeviation of 8 buffer samples in a plate).

Measurements were made on Compounds 1-17, 19, 27-38, 49-69 and 71-87.With the exception of Compound 10 at pH 6.0. Compound 31 at pH 7.0 and7.5, and Compound 38 at pH 6.0 and 7.5, all of the tested compoundsexhibited solubility ≥1 mg/ml in all the test buffers.

Example 5: Assessment of Physical Stability

Aggregation in the form of fibril formation was detected using theamyloid-specific dye Thioflavin T (ThT), which is frequently employed todemonstrate the presence of fibrils in solution (see, e.g., Groenning,M., J. Chem. Biol. 3(1) (2010), pp. 1-18; Groenning et al., J. Struct.Biol. 158 (2007) pp. 358-369; and Levine, H., III, Protein Sci. 2 (1993)pp. 404-410) Test peptides (2 mg/ml) were dissolved in demineralizedwater adjusted to pH 2.5 with HCl, at ambient temperature (typically 25°C.). Solutions containing (i) 1 mg/ml of test peptide, 40 μM ThT and 50mM phosphate (Ph) buffer (pH 7.0), (ii) 1 mg/ml of test peptide, 40 μMThT and 50 mM histidine (His) buffer (pH 7.0), and (iii) 1 mg/ml of testpeptide, 40 μM ThT and 50 mM acetate (Ac) buffer (pH 4.0), were loadedin a 96-well black fluorescence plate (clear bottom) in triplicate. Datawere collected at fixed intervals of 10 min, each preceded by 300 s ofautomixing (agitation), over a period of 96 hours at 40° C. Physicalstability, expressed as lag-time of fibril formation (in hours), wasdefined as the intersection between two linear regressions representingthe initial stable phase and the growth phase. Data are summarized inTable 1 below.

Example 6: Assessment of Chemical Stability

Samples of each test peptide were dissolved in MilliQ™ water, and the pHof the solution was adjusted to pH 4, pH 6, pH 7.5 or pH 9,respectively, using either HCl or NaOH. The final peptide concentrationwas 0.2 mg/ml. Samples were placed in glass vials and incubated at 40°C. The samples were analyzed by RP-HPLC on a C8 column with gradientelution using an ammonium formate/water eluent system, or on a C18column with gradient elution using a trifluoroacetic acid/water eluentsystem. The area-percentage (area-%) of the main peak after incubationtime T=t (relative to time T=0) was determined by UV spectroscopy at 220nm.

The purity was first determined as follows:

Purity(area-%)=(area of main peak/total area of all peaks)×100.

The purity was then normalized between time points by setting purity attime 0 (T=0) to 100 for each pH value for a given peptide, as follows:

Normalised area-% at time t (T=t)=[area-%(T=t)/area-%(T=0)]×100.

The chemical stability assessment results (in the form of normalizedpurity values) are summarized in Table 1 (below). The normalized purityvalues in Table 1 were determined after 7 days of incubation.

TABLE 1 EC₅₀ , chemical stability and fibrillation data Normalizedpurity hCTR2 hAMYR3 after 7 days, 40° C.** Fibrillation^(§§) Cmpd. EC₅₀EC₅₀ pH pH 4.0 pH 7.0 pH 7.0 No. (nM) (nM) pH 4 pH 6 7.5 pH 9 (Ac) (His)(Phos.) 1 0.079 0.230 FND FND FND 2 0.076 0.120 A A B FND FD FND 3 0.1600.200 A B B FD FD FD 4 0.210 0.220 B C C FND FND FND 5 0.200 0.180 B C CFND FND FND 6 0.077 0.220 A B B FND FND FND 7 0.087 0.340 A A A A FNDFND FND 8 0.180 0.360 A B A A FND FND FND 9 0.099 0.290 A B B B FND FDFD 10 0.160 0.350 A A B B FND FD FD 11 0.130 0.200 A B A B FND FD FD 120.120 0.250 A A B B FND FD FD 13 0.120 0.380 A A A A FND FD FD 14 0.1500.260 A A A A FND FD FND 15 0.044 0.079 A B B B FND FD FND 16 0.0730.110 A A A B FD FD FND 17 0.13 0.61 18 0.12 0.41 FND FD FD 19 0.16 0.28A A A C FND FND FND 20 0.19 0.33 FND FD FND 21 0.12 0.23 FND FD FD 220.078 0.59 FND FD FND 23 0.094 0.13 24 0.085 0.19 25 0.046 0.094 260.057 0.12 27 0.063 0.16 FD FD FD 28 0.11 0.13 A B B B FND FND FND 290.09 0.12 A B B 30 0.07 0.12 FND FD FD 31 0.09 0.29 32 0.17 0.23 FND FDFD 33 0.11 0.15 34 0.09 0.12 A B B B FND FND FND 35 0.05 0.11 A A B BFND FND FND 36 0.21 0.36 A A B B FND FND FD 37 0.04 0.07 38 0.06 0.12 390.16 0.22 40 0.12 0.19 41 0.15 0.34 B A A A 42 0.12 0.34 43 0.22 0.35 AA A A 44 0.2 0.3 45 0.16 0.31 46 0.1 0.14 47 0.1 0.19 48 0.12 0.26 A A AA FND FND FND 49 0.06 0.15 A A A B FD FND FND 50 0.12 0.19 51 0.08 0.11A B B B FND FND FND 52 0.07 0.09 A B B B FND FND FND 53 0.14 0.13 A A BB FND FND FND 54 0.08 0.14 A A B B FND FND FND 55 0.11 0.08 A A A B FNDFND FND 56 0.06 0.08 A A A B FND FND FND 57 0.08 0.11 A A A A FND FNDFND 58 0.05 0.1 A A B B FND FD FND 59 0.03 0.11 A B C B FND FD FD 600.08 0.09 A A A B FND FND FND 61 0.12 0.17 62 0.18 0.22 63 0.35 0.37 640.11 0.15 65 0.14 0.26 A A A A 66 0.19 0.30 67 0.27 0.65 68 0.32 0.29 690.12 0.17 A A B B 70 0.35 0.36 71 0.11 0.18 A A A B FND FD FD 72 0.350.27 73 0.12 0.24 74 0.58 0.39 75 0.36 0.26 76 0.44 0.49 77 0.16 0.42 AA B B FND FND FND 78 0.15 0.24 79 0.12 0.23 A A B B FND FD FD 80 0.130.28 A A A A 81 0.10 0.23 A A A A 82 0.21 0.53 83 0.13 0.32 84 0.15 0.5485 0.1 0.14 86 0.1 0.15 A A A A 87 0.2 0.13 88 0.06 A A A A FND FND FND89 0.16 0.20 A A A B FND FND FND 90 0.20 0.24 A A A A FND FND FND 910.08 0.17 A A A A FND FND FND 92 0.10 0.22 A A A A 93 0.43 95 0.18 0.20A A A A 96 0.33 0.28 A A A A FND FND FND Pramlin- 1.40 0.230 FD FD tideNN96 0.089 0.150 A A B B FND FD FD **A = >90%; B = 70-90%; C = <70%;Blank = not determined. ^(§§)FND = fibrillation not detected; FD =fibrillation detected.

Example 7: Pharmacokinetic (PK) Profiling in Rats

Compounds 6, 7, 9, 11, 13, 15, 28, 34, 36, 49, 55, 57 and 71 were testedfor their pharmacokinetic properties in rats.

Sprague Dawley male rats were given a single subcutaneous (sc) bolus ofeach peptide to be tested, as specified below. 30 nmol/kg doses ofcompound were administered. Blood samples were drawn from the tail veinprior to dosing and at 24, 48, 72, 96 and 168 hours after dosing. Bloodsamples were taken from two rats at each time point, and only 2 bloodsamples were drawn from each rat, i.e. 10 rats were used for eachcompound. The rats were euthanized immediately after the last bloodsampling by concussion and cervical dislocation.

The dosing vehicle used for each test peptide was a mannitol-containinghistidine buffer (pH 7.0). Plasma samples were analyzed afterprecipitation with ethanol by liquid chromatography mass spectrometry(LC-MS/MS). Mean plasma concentrations were used for calculation of thepharmacokinetic parameters using the non-compartmental approach inPhoenix WinNonlin 6.3.

Plasma terminal elimination half-life (t_(1/2)) was determined asln(2)/λz, where λz is the magnitude of the slope of the log linearregression of the log concentration versus time profile during theterminal phase. Apparent clearance (CL/F) was determined asdose/AUC_(inf) (sc), where AUC_(inf) is the area under the plasmaconcentration vs. time curve extrapolated to infinity(AUC_(inf)=AUC_(last)+C_(last)/λz, where C_(last) is the last observedplasma concentration).

Results

As shown in Table 2, below, the plasma terminal elimination half-livesfor all tested peptides were determined to be in the range of 14.1 hoursto 36.7 hours, while the apparent clearance values for all testedpeptides were in the range of 0.00406 to 0.0146 liter/hour/kg.

TABLE 2 Plasma terminal elimination half-lives (t_(1/2)) and apparentclearance values (Cl/F; I/h/kg) Compound No. CI/F t_(1/2) (hours) 60.0069 24.2 7 0.0087 25.4 9 0.0096 17.9 11 0.0118 14.1 13 0.0106 15.0 150.0116 18.9 28 0.0128 17.1 34 0.0148 17.2 36 0.0117 25.7 49 0.00406 36.755 0.0045 26.2 57 0.0078 17.9 71 0.0146 14.7

Example 8: Effect on Acute Food Intake and Body Weight in Normal SpragueDawley Rats

Compounds 6, 7, 9, 11, 13, 15, 28, 34, 36, 49, 55, 57, 59, 71 and 79were tested for their effect on food intake and body weight in rats.

Sprague Dawley (SD) rats were obtained from Taconic A/S, Denmark. Theanimals arrived at least 7 days before the study start to allowacclimatization to experimental conditions. From arrival and throughoutthe study, the rats were housed in groups of 2 (n=2) in a light-,temperature- and humidity-controlled room (reversed 12/12 h light/darkcycle: lights turned off during day-time and on during night-time;temperature 20-22° C.; relative humidity 50-80%). Animals had access adlibitum to food (Altromin™ 1324, Brogaarden A/S, Gentofte, Denmark) andwater (domestic quality tap water with citric acid added to pH 3.6)during the entire study. Stratification of rats was based on body weight(BW) on a cage-by-cage basis; mean BWs per cage were used as the basisfor pairing four cages together in a group (n=8 per group). A vehiclegroup and positive control group were included in each set of tests.Rats were dosed subcutaneously (sc) once in the morning immediatelybefore turning off the lights, using a body weight-corrected dose (30nmol/kg) of test peptide. Dosing volume was 5 ml/kg. Food intake wasrecorded manually at t=−24 and 0 hours (pre-dose) and at t=24, 48, 72and 96 hours after dosing. Body weight was measured daily.

Statistical analyses were performed using GraphPad™ Prism version 5. Themeasured parameters were compared using one-way ANOVA followed byDunnett's multiple comparison tests. Differences were consideredstatistically significant at p<0.05.

Results

As shown in Table 3, below, 48 hours after dosing, each of the testedcompounds had given rise to a clear, statistically significantinhibition of food intake (vehicle-corrected, in %). This reduction infood intake was reflected by a decrease in body weight(vehicle-corrected, in %) observed on day 4 post-dosing (after 96 h) inthe treated rats. (Not shown.) Normal feeding behavior was subsequentlyresumed.

TABLE 3 Acute food intake data FI inhibition after 48 h Compound No.(vehicle corrected) (%)  6 97 ± 0.2  7 94 ± 1.4  9 91 ± 2.5 11 88 ± 3.413 88 ± 2.4 15 93 ± 1.6 28 74 ± 5.4 34 70 ± 6.6 36 20 ± 3.4 49 98 ± 0.255 90 ± 2.4 57 77 ± 8.7 59 99 ± 0.1 71 84 ± 5.7 79 71 ± 5.6

Example 9: Oral Glucose Tolerance Test (OGTT) in Rats

Male Sprague Dawley rats [Crl:CD(SD), weight range 260-280 g uponarrival] were housed in groups of 2 (n=2) or 3 (n=3). The animals weremaintained on a 12 h/12 h light/dark cycle. Animals had access adlibitum to a standard chow diet and tap water (domestic quality tapwater) during the initial one week acclimatization period.

Fasted rats (fasted for 7 hours) were employed in the test. Rats hadpreviously been randomized into two groups, designated test group andcontrol group, respectively. The total number of animals per group was10 (n=10).

A single subcutaneous injection of either vehicle (control group;vehicle: 50 mM histidine buffer, pH 7, with 200 mM mannitol) or Compound7 in vehicle [test group; dose 30 nmol/kg body weight (2 ml/kg)] wassubsequently administered to each animal. All rats then received an oralglucose bolus (2 g/kg) 16 hours after vehicle or compoundadministration. Blood glucose levels in tail blood samples taken 20 min.before glucose administration (time zero, baseline) and then 15 min., 30min., 60 min., 90 min., 120 min. and 180 min after glucoseadministration were determined using a glucometer (GlucoSmart Swing™;MSP Bodmann GmbH, Germany).

Baseline glucose levels were essentially the same in the test andcontrol groups, but the elevation of glucose levels over the course ofthe 180 minute measurement time period was significantly lowered in thetest group compared to the control group. Table 4 (below) summarizes theblood glucose AUC (area under curve) determined over the period fromt=15 min. to t=180 min. from a plot of measured glucose levels as afunction of time. The data are presented as mean±S.E.M. The two-sidedunpaired Student t-test was used for statistical comparison of the testgroup and the control group.

TABLE 4 Control Test group group (Compound 7) p-value Glucose AUC, t =15-180 min. 270 ± 38 122 ± 29 p < 0.0062 (mmol/L); mean ± S.E.M.

It is clear from the results that the tested compound significantlyimproves glucose tolerance in the test group compared to the controlgroup.

Example 10: Effect of Deletion at Positions 21 and 22

The chemical stability assessment described in Example 6 was repeatedfor four pairs of compounds, each differing only by the presence orabsence of an Asn-Asn (N—N) doublet at positions 21 and 22.

TABLE 5 Compound Positions 21-22 pH 4 pH 6 pH 7.5 pH 9 NN96 N-N A A B B97 Δ A A A A 55 Δ A A A B 98 N-N A A B B 57 Δ A A A B 99 N-N A A B B 89Δ A A A A 100  N-N A A A B [Designations “A”, “B” and “C” are the sameas in Table 1. “Δ” signifies a deletion at positions 21 and 22.]

It can be seen that deletion of the Asn-Asn doublet at positions 21 and22 tends to increase chemical stability in the neutral to alkaline pHrange.

Activity at the human calcitonin (hCTR2) and amylin (hAMYR3) was alsodetermined, as described in Example 3. As shown in Table 6, the deletiontends to increase the activity at both receptors, especially incompounds containing methylated amino acid residues.

TABLE 6 hCTR2 EC₅₀ hAMYR3 EC₅₀ Compound (nM) (nM) NN96 0.089 0.150 970.10 0.13 55 0.11 0.08 98 7.2 0.38 57 0.08 0.11 99 3.8 0.59 89 0.16 0.20100  2.2 0.53

1. An amylin analogue which is a compound having the formula:R¹—Z—R² wherein R¹ is hydrogen, C₁₋₄ acyl, benzoyl or C₁₋₄ alkyl, or ahalf-life extending moiety M, wherein M is optionally linked to Z via alinker moiety L; R² is OH or NHR³, wherein R³ is hydrogen or C₁₋₃-alkyl;and Z is an amino acid sequence of formula I: (SEQ ID NO: 3)Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-X31-Val-Gly-Ser-X35-Thr- X37 (I);

wherein X3 is selected from the group consisting of Asn, Gly, Pro andGln; X10 is selected from the group consisting of Gln, Asp and Glu; X14is selected from the group consisting of Asp, His, Asn and Aad; X17 isselected from the group consisting of His, Asn, Gln, Glu, Thr, Val, Lysand Aad; X19-X20 is selected from the group consisting of Ser-Ser,Val-Val, Ser-Val and Val-Ser, or is absent; X31 is selected from thegroup consisting of Asp, Glu and Asn; X35 is selected from the groupconsisting of Asp, Glu, Asn, Ser, Phe, Orn, Aad, Gly and Thr; and X37 isselected from the group consisting of Pro, Apr and Hyp; and wherein thecompound has at least one residue selected from: X3 is Gln; X14 is His,Asn or Aad; X17 is Asn, Gln, Glu, Thr or Aad; X19-X20 is Val-Ser orSer-Val; and X35 is Ser, Phe, Orn, Aad, Gly or Thr; or apharmaceutically acceptable salt thereof. 2-4. (canceled)
 5. An amylinanalogue according to claim 1 wherein Z is an amino acid sequence offormula II: (SEQ ID NO: 4)Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35-Thr- X37 (II);

wherein X3 is selected from the group consisting of Asn, Gly and Gln;X10 is selected from the group consisting of Gln, Asp and Glu; X14 isselected from the group consisting of Asp, His and Aad; X17 is selectedfrom the group consisting of His, Asn, Gln, Glu, Lys and Aad; X19-X20 isSer-Ser or is absent; X35 is selected from the group consisting of Asp,Glu, Asn, Ser, Orn, Aad, Gly and Thr; and X37 is selected from the groupconsisting of Pro and Hyp; and wherein the compound has at least oneresidue selected from: X3 is Gln; X14 is His or Aad; X17 is Asn, Gln,Glu or Aad; and X35 is Ser, Phe, Orn, Aad, Gly or Thr.
 6. (canceled) 7.An amylin analogue according to claim 1 wherein Z is an amino acidsequence of formula III: (SEQ ID NO: 5)Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-X35- Thr-X37 (III);

wherein X3 is selected from the group consisting of Asn, Gly and Gln;X10 is selected from the group consisting of Gln, Asp and Glu; X14 isselected from the group consisting of Asp, His and Aad; X17 is selectedfrom the group consisting of His and Gln; X19-X20 is Ser-Ser or isabsent; X35 is selected from the group consisting of Asp, Glu, Asn, Aadand Gly; and X37 is selected from the group consisting of Pro and Hyp;and wherein the compound has at least one residue selected from: X3 isGln; X14 is His or Aad; X17 is Gln; and X35 is Aad. 8-17. (canceled) 18.An amylin analogue according to claim 1 wherein Z is: (SEQ ID NO: 6)RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 7)RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 8)RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp, (SEQ ID NO: 9)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp, (SEQ ID NO: 10)RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp, (SEQ ID NO: 11)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp, (SEQ ID NO: 12)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSFT-Hyp, (SEQ ID NO: 13)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGS-Orn-T-Hyp,(SEQ ID NO: 14) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp, (SEQ ID NO: 15)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSGT-Hyp, (SEQ ID NO: 16)RCNTATCATQRLAHFLHRF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 17)RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNTP, (SEQ ID NO: 18)RCNTATCATQRLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNTP, (SEQ ID NO: 19)RCGTATCATERLANFLVRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp, (SEQ ID NO: 20)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp, (SEQ ID NO: 21)RCGTATCATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp, (SEQ ID NO: 22)RCNTATCATQRLAHFLHRSVF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 23)RCNTATCATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 24)RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 25)RCPTATCATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)- LSSTDVGSDTP, (SEQ ID NO: 26)RCNTATCATQRLAHFLVRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 27)RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTDVGSNTP, (SEQ ID NO: 28)RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP, (SEQ ID NO: 29)RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTDVGSDTP, (SEQ ID NO: 30)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp, (SEQ ID NO: 31)RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp, (SEQ ID NO: 32)RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp, (SEQ ID NO: 33)RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp, (SEQ ID NO: 34)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSFT-Hyp, (SEQ ID NO: 35)RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSFT-Hyp, (SEQ ID NO: 36)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP, (SEQ ID NO: 37)RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP, (SEQ ID NO: 38)RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP, (SEQ ID NO: 39)RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP, (SEQ ID NO: 40)RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP, (SEQ ID NO: 41)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSFTP, (SEQ ID NO: 42)RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSFTP, (SEQ ID NO: 43)RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp, (SEQ ID NO: 44)RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSFT-Hyp, (SEQ ID NO: 45)RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp,(SEQ ID NO: 46) RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp, (SEQ ID NO: 47)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Apr, (SEQ ID NO: 48)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP, (SEQ ID NO: 49)RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGS-Orn-TP,(SEQ ID NO: 50) RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSTT-Hyp,(SEQ ID NO: 51) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp,(SEQ ID NO: 52) RCNTATCATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 53) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp, (SEQ ID NO: 54)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSGT-Hyp, (SEQ ID NO: 55)RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGS-Aad-T-Hyp,(SEQ ID NO: 56) RCGTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp,(SEQ ID NO: 57) RCGTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 58) RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 59) RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 60) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 61) RCPTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNT-Hyp, (SEQ ID NO: 62) RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSDT-Hyp, (SEQ ID NO: 63) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP, (SEQ ID NO: 64) RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP, (SEQ ID NO: 65) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 66) RCPTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 67) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP, (SEQ ID NO: 68) RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP, (SEQ ID NO: 69) RCPTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP, (SEQ ID NO: 70) RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 71) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp, (SEQ ID NO: 72) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp, (SEQ ID NO: 73) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp, (SEQ ID NO: 74) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp, (SEQ ID NO: 75) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp, (SEQ ID NO: 76) RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp, (SEQ ID NO: 77) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp, (SEQ ID NO: 78)RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGS-Aad-T-Hyp,(SEQ ID NO: 79) RCGTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp,(SEQ ID NO: 80) RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNTP,(SEQ ID NO: 81) RCNTATCATQRLAHFLQRF-Gly(Me)-A-Ile(Me)- LSSTEVGSGT-Hyp,(SEQ ID NO: 82) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSGTP,(SEQ ID NO: 83) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSGT-Hyp,(SEQ ID NO: 84) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSTTP,(SEQ ID NO: 85) RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSTT-Hyp,(SEQ ID NO: 86) RCNTATCATQRLAHFLERSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP,(SEQ ID NO: 87) RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSSTP,(SEQ ID NO: 88) RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 89)RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp,(SEQ ID NO: 90) RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp,(SEQ ID NO: 91) RCQTATCATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, (SEQ ID NO: 92) RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp, (SEQ ID NO: 93) RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp, (SEQ ID NO: 94) RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP, (SEQ ID NO: 95)RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNTP,(SEQ ID NO: 96) RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP, (SEQ ID NO: 97) RCQTATCATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp, or (SEQ ID NO: 98)RCQTATCATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP.


19. An amylin analogue which is a compound having the formula:R¹—Z—R² wherein R¹ is hydrogen, C₁₋₄ acyl, benzoyl or C₁₋₄ alkyl, or ahalf-life extending moiety M, wherein M is optionally linked to Z via alinker moiety L; R² is OH or NHR³, wherein R³ is hydrogen or C₁₋₃-alkyl;and Z is an amino acid sequence selected from the group consisting of:(SEQ ID NO: 99) RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSETP;(SEQ ID NO: 100) RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVGSNT-Apr; and (SEQ ID NO: 101)RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)- LSSTNVGSNT-Apr;

or a pharmaceutically acceptable salt or thereof.
 20. An amylin analogueaccording to claim 1 wherein R¹ is M- or M-L-.
 21. An amylin analogueaccording to claim 20, wherein M is an alkanoyl group.
 22. An amylinanalogue according to claim 21, wherein M is selected from15-carboxy-pentadecanoyl, 17-carboxy-heptadecanoyl and19-carboxy-nonadecanoyl.
 23. An amylin analogue according to claim 1wherein R¹ is M-L- and L is a residue of an amino acid selected from thegroup consisting of Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr,Trp, His, Lys, Arg, Gln, Asn, α-Glu, γ-Glu, ε-Lys, Asp, β-Asp, Ser, Thr,Gaba, Aib, β-Ala, 4-aminobutanoyl, 5-aminopentanoyl, 6-aminohexanoyl,7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl and8Ado.
 24. An amylin analogue according to claim 23 wherein L is a γ-Gluresidue.
 25. An amylin analogue according to claim 1 wherein R² is NH₂.26. An amylin analogue according to claim 1 which is selected from thegroup consisting of: (SEQ ID NO: 103)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂,(SEQ ID NO: 104) [19CD]-isoGlu-RCNTATCATQRLANFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂, (SEQ ID NO: 107)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 108)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 109)[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 110)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 111)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂, (SEQ ID NO: 112)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂, (SEQ ID NO: 113)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂, (SEQ ID NO: 114)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 115)[19CD]-isoGlu-RCNTATCATQRLAHFLHRF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂,(SEQ ID NO: 116) [19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂, (SEQ ID NO: 117)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂,(SEQ ID NO: 118) [19CD]-isoGlu-RCGTATCATERLANFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 119)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 120)[19CD]-isoGlu-RCGTATCATERLAHFLKRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 121)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSVF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂,(SEQ ID NO: 122) [19CD]-isoGlu-RCNTATCATQRLAHFLHRVSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP-NH₂, (SEQ ID NO: 123)[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂,(SEQ ID NO: 124) [19CD]-isoGlu-RCPTATCATDRLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂, (SEQ ID NO: 125)[19CD]-isoGlu-RCNTATCATQRLAHFLVRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂,(SEQ ID NO: 126) [19CD]-isoGlu-RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNTP-NH₂, (SEQ ID NO: 127)[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂,(SEQ ID NO: 128) [19CD]-isoGlu-RCPTATCATDRLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSDTP-NH₂, (SEQ ID NO: 129)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 130)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 131)[19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 132)[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 133)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂, (SEQ ID NO: 134)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂, (SEQ ID NO: 135)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSSTP-NH₂,(SEQ ID NO: 136) [19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂, (SEQ ID NO: 137)[19CD]-isoGlu-RCGTATCATERLAHFLERSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSSTP-NH₂,(SEQ ID NO: 138) [19CD]-isoGlu-RCGTATCATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂, (SEQ ID NO: 139)[19CD]-isoGlu-RCGTATCATERLAHFLVRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSSTP-NH₂,(SEQ ID NO: 140) [19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFTP-NH₂, (SEQ ID NO: 141)[19CD]-isoGlu-RCGTATCATERLAHFLNRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSFTP-NH₂,(SEQ ID NO: 142) [19CD]-isoGlu-RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 143)[19CD]-isoGlu-RCGTATCATERLADFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSFT-Hyp-NH₂, (SEQ ID NO: 144)[19CD]-isoGlu-RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 145)[19CD]-isoGlu-RCGTATCATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂, (SEQ ID NO: 146)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Apr-NH₂, (SEQ ID NO: 147)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSSTP-NH₂,(SEQ ID NO: 148) [19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-TP-NH₂, (SEQ ID NO: 149)[19CD]-isoGlu-RCGTATCATERLAHFLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂, (SEQ ID NO: 150)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 151)[19CD]-isoGlu-RCNTATCATQRLAHFL-Aad-RSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 152)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Orn-T-Hyp-NH₂, (SEQ ID NO: 153)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 154)[19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂, (SEQ ID NO: 155)[19CD]-isoGlu-RCGTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 156)[19CD]-isoGlu-RCGTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 157)[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 158)[19CD]-isoGlu-RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 159)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 160)[19CD]-isoGlu-RCPTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTDVGSNT-Hyp-NH₂, (SEQ ID NO: 161)[19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSDT-Hyp-NH₂, (SEQ ID NO: 162)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂,(SEQ ID NO: 163) [19CD]-isoGlu-RCNTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂, (SEQ ID NO: 164)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 165)[19CD]-isoGlu-RCPTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 166)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂,(SEQ ID NO: 167) [19CD]-isoGlu-RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂, (SEQ ID NO: 168)[19CD]-isoGlu-RCPTATCATERLADFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂,(SEQ ID NO: 169) [19CD]-isoGlu-RCNTATCATERLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 170)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 171)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 172)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 173)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 174)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂, (SEQ ID NO: 175)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂, (SEQ ID NO: 176)[19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂, (SEQ ID NO: 177)[19CD]-isoGlu-RCPTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGS-Aad-T-Hyp-NH₂, (SEQ ID NO: 178)[19CD]-isoGlu-RCGTATCATERLAHFLQRF-Gly(Me)-A- Ile(Me)-LSSTEVGSNT-Hyp-NH₂,(SEQ ID NO: 179) [19CD]-isoGlu-RCGTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂, (SEQ ID NO: 180)[19CD]-isoGlu-RCNTATCATQRLAHFLQRF-Gly(Me)-A- Ile(Me)-LSSTEVGSGT-Hyp-NH₂,(SEQ ID NO: 181) [19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂, (SEQ ID NO: 182)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 183)[19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSTTP-NH₂,(SEQ ID NO: 184) [19CD]-isoGlu-RCNTATCATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSTT-Hyp-NH₂, (SEQ ID NO: 185)[19CD]-isoGlu-RCNTATCATQRLAHFLERSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSSTP-NH₂,(SEQ ID NO: 186) [19CD]-isoGlu-RCNTATCATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSSTP-NH₂, (SEQ ID NO: 187)[19CD]-isoGlu-RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 188)[19CD]-isoGlu-RCNTATCATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp-NH₂, (SEQ ID NO: 189)[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 190)[19CD]-isoGlu-RCQTATCATDRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 191)[19CD]-isoGlu-RCQTATCATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 192)[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGT-Hyp-NH₂, (SEQ ID NO: 193)[19CD]-isoGlu-RCQTATCATDRLAHFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂,(SEQ ID NO: 194) [19CD]-isoGlu-RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP-NH₂, (SEQ ID NO: 195)[19CD]-isoGlu-RCQTATCATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSGTP-NH₂, (SEQ ID NO: 196)[19CD]-isoGlu-RCQTATCATDRLA-Aad-FLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH₂, (SEQ ID NO: 197)[19CD]-isoGlu-RCQTATCATERLAHFLQRF-Gly(Me)-A- Ile(Me)-LSSTEVGSNTP-NH₂,wherein [19CD] represents [19-carboxynonadecanoyl];

or a pharmaceutically acceptable salt thereof.
 27. An amylin analogueaccording to claim 1, comprising an intramolecular disulfide bridgeformed between the cysteine residues present at positions 2 and 7 of theamino acid sequence.
 28. A pharmaceutical composition comprising anamylin analogue according to claim 1, in combination with apharmaceutically acceptable carrier, excipient or vehicle.
 29. A devicecomprising an amylin analogue according to claim 1, for delivery of theamylin analogue to a subject.
 30. A kit comprising an amylin analogueaccording to claim 1, and optionally further comprising packaging andinstructions for use.
 31. (canceled)
 32. A method for the synthesis ofan amylin analogue according to claim
 1. 33. A method according to claim32 comprising synthesizing the amylin analogue by solid-phase orliquid-phase methodology, optionally isolating and purifying the finalproduct, and further optionally comprising the step of forming adisulfide bond between the thiol groups of the cysteine side chains atpositions 2 and
 7. 34. (canceled)
 35. A method of treating, inhibitingor reducing weight gain, promoting weight loss, reducing food intake,and/or reducing excess body weight in a subject in need, said methodcomprising administering to said subject a therapeutically effectiveamount of an amylin analogue according to claim
 1. 36. A method oftreating obesity, morbid obesity, obesity prior to surgery,obesity-linked inflammation, obesity-linked gallbladder disease,obesity-induced sleep apnea and respiratory problems, degeneration ofcartilage, osteoarthritis, or reproductive health complications ofobesity or overweight such as infertility, in a subject in need, saidmethod comprising administering to said subject a therapeuticallyeffective amount of an amylin analogue according to claim
 1. 37.(canceled)
 38. A method of prevention or treatment of Alzheimer'sdisease, diabetes, type 1 diabetes, type 2 diabetes, pre-diabetes,insulin resistance syndrome, impaired glucose tolerance (IGT), diseasestates associated with elevated blood glucose levels, metabolic diseaseincluding metabolic syndrome, hyperglycemia, hypertension, atherogenicdyslipidemia, hepatic steatosis (“fatty liver”), kidney failure,arteriosclerosis (e.g. atherosclerosis), macrovascular disease,microvascular disease, diabetic heart (including diabetic cardiomyopathyand heart failure as a diabetic complication) coronary heart disease,peripheral artery disease or stroke, and combinations thereof in asubject in need, said method comprising administering to said subject atherapeutically effective amount of an amylin analogue according toclaim
 1. 39. A method of lowering circulating LDL levels and/orincreasing HDL/LDL ratio, comprising administering an amylin analogue ofclaim
 1. 40-46. (canceled)
 47. An amylin analogue according to claim 19which is selected from the group consisting of: (SEQ ID NO 102)[19CD]-isoGlu-RCNTATCATQRLADFLHRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSETP-NH₂;(SEQ ID NO 105) [19CD]-isoGlu-RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVGSNT-Apr-NH₂; and (SEQ ID NO 106)[19CD]-isoGlu-RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-Ile(Me)-LSSTNVGSNT-Apr-NH₂;

wherein [19CD] represents [19-carboxynonadecanoyl]: or apharmaceutically acceptable salt thereof.